Document:

EX-10.15

 Exhibit 10.15 

SEATTLE GENETICS, INC. 

DEVELOPMENT AND SUPPLY AGREEMENT 

This Development and Supply Agreement (the “Agreement”) is entered into this
23rd day of February, 2004 (“Effective Date”) by and between Abbott Laboratories, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park,
Illinois 60064-3500 (“Abbott”), and Seattle Genetics, Inc. having a principal place of business at 21823 – 30th Drive Southeast in Bothell,
Washington 98021 (“Seattle Genetics”). 
 WHEREAS, Seattle Genetics is the owner of certain technology and patent rights regarding
compounds incorporating anti-CD30 monoclonal antibodies, which are used as drugs for hematologic malignancies; 
 WHEREAS, Seattle Genetics
intends to file for approval with the United States Food and Drug Administration (and its foreign equivalents), Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and/or Biologics License Applications (BLAs) (and their
foreign equivalents), for certain formulations containing Bulk Drug Substance, as defined below; 
 WHEREAS, Seattle Genetics has certain
process information relating to Bulk Drug Substance and desires to have Abbott evaluate such information and to scale-up and adapt the current manufacturing process for the preparation of Bulk Drug Substance at Abbott facilities; 

WHEREAS, Abbott possesses process engineering capabilities and operates process development facilities, which include small scale bulk drug
substance laboratories and pilot plants, as well as large scale facilities for the manufacture of clinical and commercial quantities of certain bulk drug substances; 

WHEREAS, Abbott desires to evaluate Seattle Genetics’ process information and scale-up and adapt the current manufacturing process for
the preparation of Bulk Drug Substance at Abbott facilities; and 
 WHEREAS, Abbott desires to manufacture for Seattle Genetics,
developmental, clinical and commercial quantities of Bulk Drug Substance, and Seattle Genetics desires to purchase from Abbott such quantities, all subject to the terms and conditions of this Agreement. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties hereto agree as
follows: 
  

	1.	Definitions 

 As used in this Agreement, the following words and phrases shall have the
following meanings: 
 1.1 “Abbott Inventions” means any ideas, innovations or inventions related to manufacturing (whether or not
patentable) developed by Abbott, Abbott’s Affiliates, Abbott and Third Parties, or Abbott’s Affiliates and Third Parties or prior to or during the Term, including, without limitation, Abbott Know-How and Abbott Patent Rights. 

 1.2 “Abbott Know-How” means all unique,
confidential, proprietary non-patented technical data, drawings, and related documentation, including all improvements thereto, not included in Abbott Patent Rights, as defined below, that describe the process
of manufacturing the Bulk Drug Substance as developed by Abbott for Seattle Genetics during the Project that is either (a) owned by Abbott, or Abbott’s Affiliates, or licensed to Abbott, with the right to sublicense, as of the Effective
Date, (b) generated by Abbott during the Term, or (c) acquired by Abbott (other than from or on behalf of Seattle Genetics) during the Term. 

1.3 “Abbott Patent Rights” means United States and foreign patents and patent applications, including divisions, continuations, continuations-in-part, additions, renewals, extensions, re-examinations and reissues of all such patents and patent applications, all
as are owned by Abbott, or Abbott’s Affiliates, or licensed by Abbott, with the right to sublicense, and to which Seattle Genetics would need a license in order to practice the manufacturing and/or process development operations relating to the
manufacture of Bulk Drug Substance as developed by Abbott for Seattle Genetics during the Project. 
 1.4 “Affiliate” of a Party
hereto means any entity that controls, is controlled by, or is under common control with such Party. For purposes of this definition, a Party shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty
percent (50%) of the voting equity of the other entity (or other comparable ownership interest for an entity other than a corporation). For purposes of this Agreement, TAP Pharmaceutical Products, Inc. shall be excluded from the definition of
Abbott’s Affiliates. 
 1.5 “Applicable Dollar Volume” means as such term is defined in Section 10.2. 

1.6 “Batch Records” means the mutually agreed upon final batch production and control records for the Bulk Drug Substance prepared
in accordance with 21 C.F.R. §211.188. 
 1.7 “BLA” means the Biologics License Application (or its foreign equivalent) filed
with the FDA (or foreign Regulatory Authority), seeking authorization to market Product in the United States (or applicable foreign country within the Territory). 

1.8 “Bulk Drug Pricing” means as such term is defined in Exhibit D. 

1.9 “Bulk Drug Substance” means the bulk form of the chimeric AC-10, anti-CD30 monoclonal antibody, as more fully described in
Exhibit A, manufactured in accordance with this Agreement and meeting the Bulk Drug Substance Specifications. 
 1.10 “Bulk Drug
Substance Specifications” means the written specifications for Bulk Drug Substance set forth in Exhibit B, in each case as modified from time to time pursuant to Section 7.5. 

 1.11 “Bulk Drug Substance Storage Rate” means the rate of Three Thousand Dollars
($3,000) per month per manufactured lot, provided that any fractional lots shall be considered a whole lot. 
 1.12 “cGMP” means
the FDA’s current good manufacturing practices, as first published in the Federal Register and then specified in the Code of Federal Regulations and FDA’s guidance documents, and all successor regulations and guidance documents thereto, as
well as the comparable practices, regulations and documents of any other comparable Regulatory Authorities, as in effect from time to time. 

1.13 “CMC” means the Chemistry, Manufacturing and Controls section of the BLA. 

1.14 “Calendar Quarter” means a three (3) month period commencing January 1, April 1, July 1 and October 1.

 1.15 “Confidential Information” means all information, including, but not limited to, Seattle Genetics Inventions and Abbott
Inventions disclosed pursuant to that certain Confidentiality Agreement dated July 14, 2003 between the Parties and this Agreement in writing (or all information disclosed orally, visually and/or in another intangible form which is summarized
in writing as to its general content within thirty (30) days after original disclosure and identified as being confidential), except any portion thereof that: 
  

	 	(a)	is already known to the recipient upon receipt, as evidenced by its written records; 

  

	 	(b)	is disclosed to the recipient without restriction after acceptance of this Agreement by a Third Party who has the right to make such disclosure; or 

 

	 	(c)	is independently developed by or for the recipient without reliance on the Confidential Information, as evidenced by its written records; or 

 

	 	(d)	becomes available to the general public without fault of the recipient. 

 1.16 “Contract
Year” shall mean a period of twelve (12) consecutive calendar months commencing on January 1, provided that the first Contract Year of this Agreement shall commence on Launch Date and end on the following December 31. A Contract
Year shall end upon the termination of this Agreement regardless of the actual calendar date. 
 1.17 “Convicted Individual” or
“Convicted Entity” shall mean an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §1320a – 7(a), but has not yet been excluded, debarred, suspended or
otherwise declared ineligible. 
 1.18 “Debarred Entity” shall mean a corporation, partnership or association that has been
debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from submitting or assisting in the submission of any abbreviated drug application, or an employee, partner, shareholder, member, subsidiary or affiliate of a Debarred Entity.

 1.19 “Debarred Individual” shall mean an individual who has been debarred by the FDA
pursuant to 21 U.S.C. §335a (a) or (b) from providing services in any capacity to a person that has an approved or pending drug product application, or an employer, employee or partner of a Debarred Individual. 

1.20 “Dedicated Equipment” means as such term is defined in Section 8.8. 

1.21 “Deficiency Notice” means as such term is defined in Section 9.8(a). 

1.22 “EMEA” shall mean the European Agency for the Evaluation of Medical Products, or any successor entity thereto. 

1.23 “Excluded Individual” or “Excluded Entity” shall mean (i) an individual or entity, as applicable, who has been
excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or
(ii) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services
Administration (GSA). 
 1.24 “FDA” means the United States Food and Drug Administration, or any successor entity thereto. 

1.25 “First Commercial Sale” shall mean the first sale of Product in a country within the Territory by Seattle Genetics, its
Affiliates, licensees or sublicensees to any Third Party for use or consumption of such Product in such country by the general public. 

1.26 “Force Majeure Event” means as such term is defined in Article 19. 

1.27 “Fully Burdened Manufacturing Cost” means the sum of the following costs to the extent reasonably and properly allocable to the
manufacture of Bulk Drug Substance: the cost of direct materials; direct labor; manufacturing overhead; and a reasonable allocation of general and administrative expenses and facilities expenses; provided, for purposes of clarification, that the
allocation of the foregoing costs shall be made to generally reflect the costs of plant activities incurred during the time the plant is devoted to the production of Bulk Drug Substance, and will not include any costs associated with unused plant
capacity. Fully Burdened Manufacturing Cost shall be calculated in a manner consistent with Generally Accepted Accounting Principles consistently applied. 

1.28 “ICH” shall mean the International Convention on Harmonisation and any successor agreements and/or amendments thereto. 

1.29 “Incurred Fees” means as such term is defined in Section 12.7(f). 

1.30 “Initial Order Date” means as such term is defined in Section 9.3. 

1.31 “Launch Date” means the date on which the First Commercial Sale of Product is made in the Territory by Seattle Genetics or its
designee. 

 1.32 “Liability” means any liability, judgment, loss, damage, cost and other expense
(including reasonable attorney’s fees). 
 1.33 “Maximum Quarterly Capacity” means ten (10) Kg Bulk Drug Substance per
Calendar Quarter of each Contract Year. 
 1.34 “Party” means either Abbott or Seattle Genetics individually; “Parties”
means Abbott and Seattle Genetics together. 
 1.35 “Payment Schedule” means as such term is defined in Exhibit C, which Payment
Schedule may be revised from time to time by mutual written agreement of the Parties. 
 1.36 “Product” means any pharmaceutical
product containing Bulk Drug Substance as its active ingredient. 
 1.37 “Project” means a
multi-stage (each a “Stage”) project to adapt and further develop Seattle Genetics’ current process for the manufacture of Bulk Drug Substance to Abbott’s manufacturing facility and develop
such process to commercial scale so as to manufacture Bulk Drug Substance in compliance with this Agreement, as set forth in Exhibit C. 

1.38 “Project Schedule” means the schedule for the work and Stages to be completed for the Project as will be mutually agreed to in
writing by the Parties and as may be revised and modified over time as agreed to in writing by the Parties. 
 1.39 “Purchase
Order” means any order instructions, including quantity of Bulk Drug Substance ordered, delivery date, and shipping instructions, submitted by Seattle Genetics for supply of Bulk Drug Substance. In the event of any terms of the Purchase Order
conflict with or are inconsistent with the terms of the Agreement, the terms of the Agreement shall govern and control. 
 1.40
“Quality Agreement” means as such term is defined in Section 8.4. 
 1.41 “Reassignment Costs” means as such term
is defined in Section 12.7(f). 
 1.42 “Regulatory Authority(ies)” means the FDA, the EMEA, the ICH, or any comparable
national or territorial regulatory entity within the Territory. 
 1.43 “Regulatory Filings” means the governmental filings
required to commence human clinical trials and to obtain approval to market Product in a given country within the Territory, including, but not limited to, Product registration(s) and marketing approval(s), as applicable, in each such country. 

1.44 “Research and Development Fee” means as such term is defined in Section 5.1. 

1.45 “Reservation Rate” means as such term is defined in Section 2.3. 

1.46 “Reserved Capacity” means as such term is defined in Section 2.3. 

 1.47 “Response Notice” means as such term is defined in Section 9.8(b). 

1.48 “Rolling Forecast” means as such term is defined in Section 9.4. 

1.49 “Seattle Genetics Know-How” means all unique, confidential, proprietary non-patented
technical data, drawings, documentation, analytical and regulatory information and other information, including all improvements thereto, not included in Seattle Genetics Patent Rights, as defined below, relating to the manufacture, use or sale of
Bulk Drug Substance that is either (a) owned by Seattle Genetics (or Seattle Genetics’ Affiliates), or licensed to Seattle Genetics, with the right to sublicense, as of the Effective Date, (b) generated by Seattle Genetics during the
Term, or (c) acquired by Seattle Genetics (other than from or on behalf of Abbott) during the Term. 
 1.50 “Seattle Genetics
Patent Rights” means the United States (listed on Exhibit G) and foreign patents and patent applications, including divisions, continuations, continuations-in-part,
additions, renewals, extensions, re-examinations and reissues of all such patents and patent applications, all as are owned by Seattle Genetics (or Seattle Genetics’ Affiliates), or licensed to Seattle
Genetics, with the right to sublicense, claiming Bulk Drug Substance, or to which Abbott would need a license or sublicense in order to make Bulk Drug Substance. 

1.51 “Stage” means as such term is defined in Section 1.37. 

1.52 “Term” means as such term is defined in Section 12.1. 

1.53 “Territory” means the world. 

1.54 “Third Party” or Third Parties” means any person(s) or entity(ies), as applicable, other than the Parties, their
Affiliates, or the Parties and Affiliates employees and agents. 
  

	2.	Bulk Drug Substance Development Project 

 2.1 The Project. Following the Effective
Date and according to technical reports and the project plan set forth in Exhibit C, Abbott shall undertake the Project. The Project shall consist of research and development activities described on Exhibit C. Abbott shall perform its research and
development activities hereunder pursuant to the terms of this Agreement and the Project; provided, however, Seattle Genetics understands that, because the Project involves research from which the results are inherently uncertain, Abbott does not
make any representation, warranty or guarantee of any kind that the Project will result in a commercially-viable process. Nevertheless, Abbott shall conduct the Project diligently and in accordance with
generally accepted standards of good scientific practice including, but not limited to, the creation and maintenance of properly witnessed complete and accurate laboratory notebooks made contemporaneous with the activities reflected therein. 

2.2 Project Stages. At the completion of each Stage, except in the event that this Agreement is otherwise terminated as permitted
herein, the Parties shall mutually agree whether to (i) proceed with the Project; (ii) conduct further development work under the then current Stage in addition to those activities described in the Project for the then current Stage; or
(iii) terminate this Agreement. In the event, that the Parties cannot 

 
agree on (i), (ii) or (iii) above, the Parties shall organize representatives with technical and executive decision making authority, to meet in good faith and attempt to mutually agree
on (i), (ii) or (iii). If the Parties are unable to reach agreement at any Stage within ninety (90) days of initiating discussions, then either Party shall have the right to terminate the Agreement pursuant to Sections 12.2 (termination by
Seattle Genetics) or 12.3 (termination by Abbott). 
 2.3 Manufacturing Facility Reservation. Abbott shall reserve capacity for the
Stage IIIa (as set forth in the Exhibits hereto) engineering and cGMP clinical supply batches and Seattle Genetics shall agree to pay for said reservation in Abbott’s commercial manufacturing facility, on the date two (2) months prior to
the initiation of Stage IIIa (currently estimated to be March 8, 2004) based on the then current Project Schedule, as may be revised by the Parties (the “Reserved Capacity”). The Reservation rate shall be One Million Five Hundred
Thousand Dollars (US $1,500,000) per Stage IIIa engineering or clinical supply batch (the “Reservation Rate”) in accordance with the then current Project Schedule; provided however, that the aggregate Reservation Rate to complete Stage
IIIa, which shall be agreed by the Parties in writing prior to Stage IIIa, shall not exceed Six Million Dollars (U.S. $6,000,000). Beginning on or around May 1, 2004, Abbott shall initiate the manufacture of one (1) engineering batch,
followed by three (3) cGMP clinical supply batches meeting Bulk Drug Substance Specifications. Seattle Genetics, at its sole option, may (i) defer receipt and payment of the third clinical supply batch until January 3, 2005; or
(ii) refuse delivery of the third clinical supply batch within ten (10) business days immediately following January 3, 2005. If Seattle Genetics, at its sole option chooses (ii) above, the amount Seattle Genetics shall pay to
Abbott as part of the Reservation Rate shall be adjusted by payment or refund to equal Six Hundred Twenty Five Thousand Dollars (U.S. $625,000), net thirty (30) days from the date of receipt of Abbott’s invoice, as a loss of business
opportunity for Abbott. Once any such capacity Reservation occurs, and the initiation date for work in the commercial facility has passed, Abbott shall begin to invoice Seattle Genetics monthly according to the Payment Schedule. In the event that
Seattle Genetics does not utilize the total number of batches of the Reserved Capacity to fulfill the Project obligations, the amount Seattle Genetics shall pay to Abbot shall be adjusted, by payment or refund, to equal Four Million Dollars (U.S.
$4,000,000) of the aggregate Reservation Rate due Abbott pursuant to this Section 2.3. Notwithstanding the foregoing, if Abbott is able to resell any of its unused capacity for the Reserved Capacity, it shall provide Seattle Genetics with a
reasonable credit, offset or refund (as elected by Seattle Genetics) in an amount to be determined in good faith by Abbott. 
  

	3.	Abbott’s Research and Development Activities  

 3.1 Abbott’s Activities.
One of the objectives of the Project shall be for Abbott to develop and manufacture Bulk Drug Substance and to support Seattle Genetics’ Regulatory Filings as appropriate, however, Seattle Genetics shall be responsible for the preparation and
filing of Regulatory Filings, and all communications with Regulatory Authorities, with respect to the Bulk Drug Substance. Abbott shall conduct and perform its obligations on the work-plan set forth in Exhibit C as may be amended from time to time
by mutual agreement of the Parties to achieve such objectives, including, but not limited to, the following: 
  

	 	a.	Sourcing raw materials for use in manufacturing Bulk Drug Substance, with the price of such materials excluded from the price of the Project up to commercial production 

	 	b.	Performing pilot scale evaluation of Seattle Genetics’ manufacturing process; 

  

	 	c.	Adapting Seattle Genetics’ manufacturing process to Abbott’s equipment and systems;  

  

	 	d.	Developing optimized process parameters to manufacture Bulk Drug Substance in Abbott’s manufacturing facility; 

  

	 	e.	Preparing suitable manufacturing process documentation, including instructions and manufacturing controls for inclusion in Regulatory Filings; 

 

	 	f.	Provide the Bulk Drug Substance information directly to Seattle Genetics in support of Regulatory Filings, and assisting Seattle Genetics in responding to questions from Regulatory Authorities concerning the manufacture
of Bulk Drug Substance; 

  

	 	g.	Conducting material contact and cleaning validation studies, engineering and validation runs, process validation studies, and preparing process justification and validation summary reports, in a mutually agreed upon
timely manner, to meet pre-approval and other appropriate inspection requirements of the Regulatory Authorities and to support approval of the manufacture of the Bulk Drug Substance in an Abbott manufacturing
facility; 

  

	 	h.	Permitting Seattle Genetics to conduct all necessary cGMP and quality assurance reviews of Abbott documentation, including review and receipt of copies of Abbott manufacturing work orders; 

 

	 	i.	Permitting Seattle Genetics to access Abbott’s manufacturing data relating to Bulk Drug Substance; 

  

	 	j.	Providing Seattle Genetics with acceptable environmental impact statements, if required, for inclusion with Regulatory Filings; 

  

	 	k.	Providing Seattle Genetics with appropriate pilot and commercial scale batch record manufacturing documentation for Regulatory Filings and other uses in accordance with the Quality Agreement; 

 

	 	l.	Preparation for and administration of the pre-approval inspection (and any other necessary inspections) by the Regulatory Authorities; and 

 

	 	m.	Subject to Section 2.1, manufacturing development supplies, clinical supplies and process validation batches of Bulk Drug Substance in accordance with current cGMPs and pursuant to protocols to which the Parties
shall mutually agree. 

	4.	Seattle Genetics’ Research and Development Activities 

 4.1 Seattle
Genetics’ Activities. Seattle Genetics shall assist Abbott in completing the Project, including but not limited to Seattle Genetics’ responsibility for the following: 

 

	 	a.	Providing Abbott with materials as detailed in Exhibit M. 

  

	 	b.	Providing Abbott with applicable analytical methods qualified to Abbott’s standards for raw materials which standards shall reasonably comport with industry standards, in-process tests and manufacture of Bulk Drug
Substance and all available reference materials; 

  

	 	c.	Providing Abbott with technical data on Bulk Drug Substance that includes, but is not limited to, the following: (i) material safety data sheets with environmental and safety information, and (ii) additional
detailed data, if necessary, to define potential hazards and establish employee exposure levels; 

  

	 	d.	Obtaining and providing Abbott with copies of Regulatory Filings as necessary for Abbott to obtain regulatory approval of the pre-approval inspection; and 

 

	 	e.	Maintaining a stability program for, and retaining samples of, the Bulk Drug Substance. 

  

	5.	Payment for Abbott’s Development Efforts 

 5.1 Research and Development Fee.
To reimburse Abbott for its participation in the Project in compliance with the activities described therein and in this Agreement, and in accordance with the Payment Schedule, Seattle Genetics shall pay Abbott a research and development fee
(“Research and Development Fee”), which fee in the aggregate upon completion of the Project may be less than or equal to, but shall not exceed, Seven Million Eight Hundred Ninety Thousand Dollars (U.S.$7,890,000), unless revisions occur in
the Project scope in accordance with the terms of this Article 5. The Parties understand and agree that the Research and Development Fee is comprised of, in part, on a dollar for dollar basis, the Reservation Rate described in Section 2.3. The
Research and Development Fee shall be paid to Abbott as outlined in the Payment Schedule. Any such modifications agreed upon by the Parties to the scope of the Project shall be incorporated into the Payment Schedule by a written agreement between
Seattle Genetics and Abbott. 
 5.2 Changes in Project Scope. If changes occur in the Project or Bulk Drug Substance Specifications,
or if technical difficulties require that Abbott perform either additional work or repeat work, and provided such work is unrelated to Abbott’s fault or negligence, in advance of incorporating such changes or performing any work associated
therewith, Abbott shall consult with Seattle Genetics and thereafter provide Seattle Genetics with a new or revised written test protocol with cost estimates for such work. If Seattle Genetics approves such fee and protocols, Abbott shall perform
such work and Seattle Genetics shall pay Abbott’s fee for such work in the manner and at the time as agreed upon by the Parties in conjunction with the approval of the work. 

 5.3 Additional Filing Costs. Seattle Genetics shall reimburse Abbott for Abbott’s
reasonable out of pocket costs paid to any Third Party, which are subject in each case to written pre-approval by Seattle Genetics, associated with any filings with Regulatory Authorities including but not limited to the filing of a CMC or CMC
amendment, in support of Seattle Genetics’ Regulatory Filings with respect to Bulk Drug Substance. Seattle Genetics also shall reimburse Abbott for those reasonable out of pocket costs paid to any Third Party, which are subject in each case to
written pre-approval by Seattle Genetics, for any work requested by Seattle Genetics to produce and assemble documentation for Bulk Drug Substance registrations outside the United States. Seattle Genetics shall not be obligated to pay or reimburse
Abbott any of its costs associated with its establishment license or otherwise relating to its qualification as a manufacturer of biological product for human use, except in the event that such costs are uniquely attributable to the manufacture of
Bulk Drug Substance, in which event, Seattle Genetics shall be responsible for such costs. 
  

	6.	Pilot Scale and Clinical Supplies 

 6.1 Pilot Scale Supplies. Subject to
Section 2.1, as part of the development portion of the Project, Abbott shall manufacture and provide to Seattle Genetics product that results from up to (as determined by Seattle Genetics) two (2) three hundred liter (300L) pilot
scale lots of Bulk Drug Substance. Apart from Section 2.1, and notwithstanding any other terms or conditions to the contrary contained herein, including, without limitation Section 13.2, Abbott makes no warranties, express or implied, with
respect to Bulk Drug Substance produced for pilot scale supplies pursuant to this Section 6.1. All warranties, express or implied, including without limitation, the implied warranties of merchantability, fitness for a particular purpose and
non-infringement, are hereby disclaimed by Abbott with respect to Bulk Drug Substance manufactured pursuant to this Section 6.1. 
 6.2
2004 Clinical Supplies. Subject to Section 2.1, as part of completing the Project, Abbott shall manufacture and provide to Seattle Genetics Bulk Drug Substance supplies that result from four (4) 3,000L runs that are scheduled as one
(1) engineering run and three (3) cGMP clinical supply lots. In order to agree on final Batch Records and binding Bulk Drug Substance Specifications for clinical manufacture, Abbott will perform one (1) engineering run at the 3000L
scale. This engineering run will be based upon preliminary Batch Records and Bulk Drug Substance Specifications as provided by Seattle Genetics and transferred to Abbott. The Parties shall mutually agree upon final batch records and specifications
following the engineering run prior to the start of cGMP clinical manufacture. Abbott shall then deliver three (3) cGMP clinical supply lots according to the mutually agreed final Batch Records and Bulk Drug Substance Specifications. Abbott
warrants the cGMP clinical supply lots in accordance with Section 13.2. Seattle Genetics shall promptly notify Abbott of any alteration of the Project Schedule and Bulk Drug Substance amount. 

6.3 Additional Clinical Supplies. Approximately six (6) months in advance of the desired clinical supply Bulk Drug Substance start
date, Seattle Genetics shall provide Abbott a non-revocable Purchase Order for its requirements of Bulk Drug Substance to be supplied by Abbott. The price of Bulk Drug Substance purchased pursuant to this Section 6.3 shall be One Million Five
Hundred Thousand Dollars (U.S. $1,500,000), excluding raw material costs, per batch, subject to Section 7.5. Abbott warrants the cGMP clinical supply lots in accordance with Section 13.2. 

 6.4 Revisions to Schedule. No revisions may be made to the pilot scale and clinical
development schedule portion of the Project Schedule unless mutually agreed upon in writing by Seattle Genetics and Abbott. The Parties shall mutually agree to the revision in fees associated with such agreed upon adjustment to such schedule. 

 

	7.	Manufacture and Commercial Supply of Bulk Drug Substance 

 7.1 Purchase and Sale of
Bulk Drug Substance. During the Term, Abbott shall manufacture and deliver Bulk Drug Substance, in accordance with the terms of this Agreement, for the benefit of Seattle Genetics or its designee, and Seattle Genetics shall purchase, in
accordance with the terms of this Agreement, its Bulk Drug Substance requirements in the Territory up to the Maximum Quarterly Capacity from Abbott provided that Abbott is able to supply Bulk Drug Substance in accordance with Article 9. Seattle
Genetics shall have the right, in an effort to ensure a secure supply of Bulk Drug Substance, to enter into a commercial-scale supply contract with a company other than Abbott for the supply of up to thirty percent (30%) of Seattle
Genetics’, its Affiliates, subsidiaries, licensees, sublicensees and contractors’ worldwide commercial supply requirements of Bulk Drug Substance (the “Second Source”). Seattle Genetics hereby agrees that Abbott may qualify, in
the sole discretion of Seattle Genetics, as the Second Source if Abbott can demonstrate its ability to supply thirty percent (30%) of Seattle Genetics’, its Affiliates, subsidiaries, licensees, sublicensees and contractors’ worldwide
commercial supply requirements of Bulk Drug Substance from a physically separate facility more than 500 miles away from the manufacturing site supplying any other portion of Seattle Genetics’ requirements of Bulk Drug Substance. Abbott shall
manufacture Bulk Drug Substance in accordance with the Bulk Drug Substance Specifications that the Parties shall mutually develop. The Parties may alter from time to time the Bulk Drug Substance Specifications by mutual written agreement without
amending this Agreement in accordance with Section 7.5. In the event that Abbott intends to manufacture an anti-CD30 monoclonal antibody for any Third Party (except for TAP Pharmaceutical Products, Inc. or its subsidiaries) at any time during
the Term, then within thirty (30) days after Abbott signs a final agreement with such Third Party, Abbott shall notify Seattle Genetics of such final agreement and Seattle Genetics shall have the one-time right, to be exercised within ninety
(90) days after receipt of such notice from Abbott, to provide Abbott with twelve (12) months prior notice that Seattle Genetics is entering into a commercial-scale supply contract with a Third Party for the supply of up to seventy percent
(70%) of Seattle Genetics’, its Affiliates, subsidiaries, licensees, sublicensees and contractors’ worldwide commercial supply requirements of Bulk Drug Substance. Seattle Genetics shall have the option exercisable at any time during
this Agreement, after the completion of Stage IIIa, to either (i) terminate this Agreement in accordance with Section 12.2, provided however, that Seattle Genetics or its licensee, as applicable, agrees to purchase at least seventy percent
(70%) of its commercial requirements of Bulk Drug Substance from Abbott in accordance with this Section 7.1 for a period of at least three (3) years after the Launch Date; or (ii) terminate this Agreement in accordance with
Section 12.2 and pay to Abbott Five Million Dollars (U.S. $5,000,000) net thirty (30) days after Seattle Genetics’ receipt of Abbott’s invoice. 

7.2 Raw Materials and Components. Abbott shall source all raw materials and components necessary for the manufacture of the Bulk Drug
Substance. Such raw materials and components are included in the commercial price of the Bulk Drug Substance as detailed in Exhibit D. 

 7.3 Use of Third Parties. Abbott shall not utilize a Third Party to manufacture any
portion of the Bulk Drug Substance without first obtaining Seattle Genetics’ written consent, which consent shall not be unreasonably withheld, conditioned or delayed. In the event that Abbott is authorized to utilize a Third Party in the
manufacture of Bulk Drug Substance, such Third Party shall be approved by Abbott’s Quality Assurance department. Any such contract entered into by Abbott and a Third Party shall contain provisions substantially similar to those set forth in
this Agreement pertaining to the audit of Abbott, that allow Seattle Genetics to audit such Third Party’s facilities. Abbott agrees that it shall remain liable for the performance of Abbott’s obligations hereunder in the event that Abbott
is authorized to use a Third Party to perform certain of Abbott’s obligations on its behalf. It shall be deemed reasonable for Seattle Genetics to withhold consent to Abbott’s utilization of a Third Party to manufacture any portion of the
Bulk Drug Substance in the event that such utilization would have a substantial likelihood of (a) impairing or jeopardizing any pending or actual regulatory approval for the manufacture of the Bulk Drug Substance, (b) adversely affecting
the regulatory status of the Bulk Drug Substance or (c) materially delaying delivery schedules, increasing the pricing or adversely affecting the quality of the Bulk Drug Substance. 

7.4 THIS SECTION HAS BEEN INTENTIONALLY OMMITTED BY THE PARTIES. 

7.5 Modification of Bulk Drug Substance Specifications. Abbott shall not implement any modification, material or otherwise, to the Bulk
Drug Substance Specifications without Seattle Genetics’ prior written approval. Abbott shall submit to Seattle Genetics a revised price for either the current or future Stage of development during the Project or the Bulk Drug Substance that
reflects such cost increase or decrease resulting from any of the following events: (i) the Bulk Drug Substance Specifications are modified by Seattle Genetics, (ii) the Bulk Drug Substance Specifications must be modified by requirement of
any Regulatory Authority, or (iii) a process change is required as part of the CMC or other applicable governmental application, and such modification or process change materially increases or decreases Abbott’s cost to manufacture Bulk
Drug Substance. Abbott and Seattle Genetics shall mutually agree on the cost allocation of such change. In the event the Parties are unable to agree on such cost allocation, Abbott may refuse to implement the change in which event, Seattle Genetics
may terminate this Agreement in accordance with Section 12.2. If such modification results in the requirement to reprocess and/or retest previously manufactured and otherwise acceptable Bulk Drug Substance, any additional costs incurred by
Abbott in such reprocessing and/or retesting shall be paid within the longer of: (i) sixty (60) days of the mutual written agreement of the Parties for Abbott to reprocess and/or retest the Bulk Drug Substance; or (ii) thirty
(30) days after receipt of the final report of the results of the retest or reprocessing. The Parties hereby acknowledge that it is their joint objective to develop and implement a manufacturing process that is as efficient and cost effective
as possible, and to continue to improve its efficiency, as maybe permitted by Regulatory Authorities. During the Term, the Parties shall discuss and negotiate in good faith regarding the impact of implementation of a scale-up process and/or improved
process, which may result in a cost reduction. 

 7.6 Modification of Bulk Drug Substance Process. Abbott shall not make any process changes
with respect to the manufacture of the Bulk Drug Substance without prior written permission from Seattle Genetics. Abbott shall not make any facility changes with respect to the manufacture of the Bulk Drug Substance without providing Seattle
Genetics with prior written notice. Prior to any such change being made, Seattle Genetics shall be responsible for obtaining (a) all necessary approvals from Regulatory Authorities and (b) to the extent necessary and under terms to be
agreed upon in writing by Seattle Genetics, licensure from Abbott or any Third Party in order to practice such process change for the manufacture of Bulk Drug Substance with respect to such modifications. Modifications to Abbott’s facilities
and the cost thereof resulting from a change in law, rule, or regulation shall be the responsibility of Abbott, except to the extent that such costs are uniquely attributable to the manufacture of Bulk Drug Substance, in which case Seattle Genetics
shall be responsible for such costs. Abbott shall be solely responsible for obtaining any necessary approvals from Regulatory Authorities for facility changes. 
  

	8.	Manufacture of Bulk Drug Substance 

 8.1 Bulk Drug Substance Title and Shipment.
Any Bulk Drug Substance manufactured by Abbott pursuant to this Agreement shall be shipped F.O.B. Abbott’s manufacturing facility using validated shipping methods, which shall be part of the Bulk Drug Substance Specifications. Risk of loss,
including, without limitation responsibility for payment to Abbott for such Bulk Drug Substance, shall pass to Seattle Genetics upon delivery of Bulk Drug Substance to the carrier; provided, however, that title to the Bulk Drug Substance shall not
pass to Seattle Genetics until the Bulk Drug Substance arrives at Seattle Genetics’ designated shipping destination. Shipment shall be via a carrier designated by Seattle Genetics. Abbott shall not ship any Bulk Drug Substance that does not
conform to the Bulk Drug Substance Specifications. Each shipment of Bulk Drug Substance shall be accompanied by documentation in accordance with Exhibits B (Bulk Drug Substance Specifications) and H (Quality Agreement). 

8.2 Bulk Drug Substance Storage. Seattle Genetics shall pay Abbott for any Bulk Drug Substance storage costs at the Bulk Drug Substance
Storage Rate (excepting retained samples) incurred by Abbott at Seattle Genetics’ request for storage after the period ending sixty (60) days after release of post Launch Date Bulk Drug Substance, provided that such Bulk Drug Substance was
forecasted by Seattle Genetics according to Article 9. 
 8.3 Quality Control. Abbott shall apply its quality control procedures and in-plant quality control checks on the manufacture of Bulk Drug Substance for Seattle Genetics in the same manner as Abbott applies such procedures and checks to bulk drug substance of similar nature manufactured
for sale by Abbott, which in all events will at least meet generally accepted standards of quality control in the manufacture of biologics in the pharmaceutical industry. In addition, Abbott will test and release Bulk Drug Substance to Seattle
Genetics in accordance with the Bulk Drug Substance Specifications described in Exhibit B. 
 8.4 Quality Assurance. Within forty
five (45) days after the Effective Date, representatives of the Parties shall meet to develop and approve a quality agreement (“Quality Agreement”) which will be attached hereto as Exhibit H, outlining the responsibilities and key
contacts for quality and compliance-related issues. Items to be contained in the Quality Agreement include, but are not limited to recalls, annual product reviews, returned goods, regulatory audits, compliance with cGMP and compliance with such
other quality related concerns as are deemed appropriate by the Parties. 

 8.5 Audits. Seattle Genetics shall have the right, upon seven (7) days’ prior
written notice to Abbott and receipt of Abbott’s consent thereto, which consent shall not be unreasonably withheld, conditioned or delayed, to conduct during normal business hours a quality assurance audit and inspection of Abbott’s
records and Bulk Drug Substance facilities relating to the manufacture of Bulk Drug Substance and to perform follow-up audits as reasonably necessary. Prior to Abbott commencing the production of the first
batch of commercial Bulk Drug Substance as ordered by Seattle Genetics, such audits and inspections may be conducted from time to time on a reasonable basis. Once Abbott has commenced production of the first batch of commercial Bulk Drug Substance,
such audits may only be conducted once each calendar year. The duration of such audits shall not exceed three (3) days and such audits shall be performed by no more than three (3) auditors, unless Seattle Genetics reasonably believes that
a longer audit or additional personnel are necessary and provides its reasonably adequate reasons for such belief to Abbott in writing. If Seattle Genetics wishes to perform audits more often than once per year or over a period in excess of three
(3) days, Seattle Genetics shall pay Abbott Seven Thousand Five Hundred Dollars (U.S.$7,500) per additional audit day. Notwithstanding the foregoing, in the event that an audit is required by Seattle Genetics due to quality issues that arise,
per the terms of Sections 8.6 and/or 9.8, Seattle Genetics shall be entitled to conduct one additional audit for each such occurrence free of charge. If more than three (3) auditors perform the audit, Seattle Genetics shall pay Abbott Seven
Thousand Five Hundred Dollars (U.S.$7,500) per additional auditor. In addition, Seattle Genetics or its licensees shall have the right at any time during the Term, upon three (3) business days prior written notice to Abbott, to conduct any
audits specifically mandated by any Regulatory Authority or to respond to specific questions from any such Regulatory Authority. Notwithstanding anything to the contrary contained in this Agreement, any audits conducted on Abbott’s property
shall be subject to Abbott’s rules and regulations regarding, without limitation, security and confidentiality and shall be conducted in the presence of Abbott’s employees. In addition, Abbott shall promptly provide Seattle Genetics a
written response to any such audit report received by Abbott. 
 Visits by Seattle Genetics to Abbott’s Bulk Drug Substance facilities
may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11
and shall not be disclosed to Third Parties, including but not limited to any Regulatory Authority, unless required by law and upon prior written notice to Abbott. If Seattle Genetics utilizes auditors that are not employees of Seattle Genetics,
each of such auditors shall execute a non-disclosure agreement with confidentiality terms at least as stringent as those set forth in Article 11. 

Abbott shall be responsible for inspections of its manufacturing facilities by any Regulatory Authorities and shall promptly notify Seattle
Genetics if such inspections are directly related to the manufacture of Seattle Genetics’ Bulk Drug Substance or if the results of a non-related inspection could materially impair Abbott’s ability to perform in accordance with this
Agreement. With respect to inspections related to the manufacture of Bulk Drug Substance, Abbott shall (a) provide Seattle Genetics with copies of all documents, reports or communications received from or given to any Regulatory Authority
associated therewith, (b) permit Seattle Genetics’ representatives to be present 

 
on site at such inspections, and to participate, at Abbott’s reasonable discretion, as appropriate, based on questions or requests specific to Seattle Genetics and as permitted by Regulatory
Authorities, in such inspections, and (c) allow Seattle Genetics to provide comments to Abbott, and Abbott shall draft any such correspondence to Regulatory Authorities in connection therewith. 

Seattle Genetics shall promptly notify Abbott regarding any inspection on Seattle Genetics property related to the manufacture of Bulk Drug
Substance. 
 8.6 Recalls. Product recalls and contacts with any Regulatory Authorities relating to the recall of Product shall be
the responsibility and under the control of Seattle Genetics. In the event that Abbott has reason to believe that any Products should be recalled or withdrawn from distribution, it shall promptly inform Seattle Genetics in writing of such belief.
Seattle Genetics shall notify the appropriate Regulatory Authorities of any recall and shall be responsible for coordinating all necessary activities regarding the action taken. Abbott and Seattle Genetics shall fully cooperate to complete the
recall, and shall thereafter resolve any allocation of liability as may be appropriate in accordance with the terms of this Agreement. The costs and expenses of conducting any recall shall be treated as follows: 

(a) If any Product is recalled as a result of the supply by Abbott of Bulk Drug Substance that was not manufactured in compliance with the
terms of this Agreement, then Abbott shall reimburse Seattle Genetics for all reasonable expenses actually incurred as a result of such recall including the cost of the Bulk Drug Substance. If Seattle Genetics elects to utilize a Third Party to
conduct a recall, Seattle Genetics shall notify Abbott of the identity of such Third Party; 
 (b) If each Party contributes to the cause for
a recall, the expenses actually incurred as a result of such recall will be shared in proportion to each Party’s responsibility; and 

(c) All recalls of Product other than those described in clauses (a) or (b) shall be at Seattle Genetics’ sole expense. Seattle
Genetics shall give Abbott prompt written notice of any Product recalls that Seattle Genetics believes were caused or may have been caused by Abbott’s failure to comply with this Agreement. 

 

	8.7	Payment Terms 

 (a) Price and Payment. For (a) work performed in conducting
the Project in accordance with this Agreement, (b) Deliverables to Seattle Genetics as specified in Exhibit C, and (c) Bulk Drug Substance that is manufactured and delivered in accordance with this Agreement and meets the Bulk Drug
Substance Specifications, Abbott shall invoice Seattle Genetics according to the Payment Schedule and Bulk Drug Pricing in Exhibit D. Seattle Genetics shall make payment of all undisputed amounts net thirty (30) days from the date of receipt of
Abbott’s invoice; provided that with respect to payments owed by Seattle Genetics for Reserved Capacity pursuant to Section 2.3, payment terms shall be net sixty (60) days from the date of receipt of Abbott’s invoice. All
payments due under this Agreement shall be paid in U.S. Dollars by wire 

 
transfer (Seattle Genetics will endeavor but is not obligated to provide twenty four (24) hours advance notice of each wire transfer to the bank account identified below or such other bank
accounts as Abbott shall designate in writing to Seattle Genetics) or by such other means agreed to by the Parties, for value, in each case at the expense of the payor: 
  

			
	Account Name:		Abbott Laboratories
	Account Number:		3019-9333
	Bank:		Northern Trust of Chicago
			Chicago, Illinois
	ABA Number:		071000152

 (b) Taxes. Any federal, state, county or municipal sales or use tax, excise, customs charges, duties or
similar charge, or any other tax assessment (other than that assessed against income, real property, or the right of Abbott to do business), license, fee or other charge lawfully assessed or charged on the manufacture, sale or transportation of Bulk
Drug Substance sold pursuant to this Agreement shall be paid by and the responsibility of Seattle Genetics. 
 8.8 Dedicated
Equipment. Seattle Genetics shall pay the cost of additional equipment purchased by Abbott (“Dedicated Equipment”), which is required for Abbott to manufacture Bulk Drug Substance for Seattle Genetics (subject to the approval
conditions stated below). Abbott shall advise Seattle Genetics of any Dedicated Equipment required and the estimated costs associated with the purchase, installation and validation of such Dedicated Equipment. Abbott must receive written approval
(letter, e-mail or facsimile) by an authorized Seattle Genetics representative prior to the purchase of any such Dedicated Equipment. Such Dedicated Equipment shall be used exclusively for manufacturing of Bulk Drug Substance hereunder, unless
otherwise permitted in advance by Seattle Genetics in writing. If Seattle Genetics authorizes the use of such Dedicated Equipment for other products, Abbott shall provide Seattle Genetics with a credit in the reasonable amount of prorated cost(s) of
the Dedicated Equipment (based on relative time of usage for each product). Abbott shall bill Seattle Genetics for the reasonable installation and equipment validation costs after Abbott installs the Dedicated Equipment. This Section 8.8 shall
not apply to any replacement equipment purchased by Abbott because of obsolescence (technical or otherwise). Dedicated Equipment, as estimated on or around the Effective Date, is outlined in Exhibit F. Abbott shall own any Dedicated Equipment. In
the event this Agreement is terminated, Abbott and Seattle Genetics shall in good faith agree on the commercially reasonable procedures and costs related to the transfer of title to and possession of Dedicated Equipment to Seattle Genetics. Seattle
Genetics agrees and acknowledges that upon termination of this Agreement, unless otherwise agreed in accordance with this Section, Seattle Genetics shall own such Dedicated Equipment and shall remove its Dedicated Equipment from Abbott’s
property within thirty (30) days after the termination of the Agreement. Upon such termination, if Abbott wishes to retain any such Dedicated Equipment (in Abbott’s sole discretion), and Seattle Genetics approves of such retention in
writing, Abbott shall reimburse Seattle Genetics for such retained Dedicated Equipment at its then current book value. In addition to Exhibit F, Abbott shall submit quarterly to Seattle Genetics, an updated estimate of Dedicated Equipment costs for
the entire Project. 

 Title to, and risk of loss of, all Dedicated Equipment shall be retained by Seattle Genetics;
provided, however, that Abbott shall be responsible for replacing any Dedicated Equipment that is destroyed due to Abbott’s negligence, willful misconduct, unauthorized use or unauthorized use with other products. All Dedicated Equipment shall
remain at Abbott’s manufacturing facilities. 
 Abbott shall be responsible for maintaining and servicing the Dedicated Equipment.
Seattle Genetics, however, shall be responsible for the cost of non-routine maintenance and servicing of the Dedicated Equipment (such as major repairs and material parts replacement), except to the extent caused by Abbott’s negligence, willful
misconduct, unauthorized use or use with other products in which case Abbott shall be responsible. Abbott shall notify Seattle Genetics prior to the performance of any non-routine maintenance or servicing, and Seattle Genetics shall reimburse Abbott
at cost for such maintenance or servicing costs that Seattle Genetics has authorized to be incurred and for which it is responsible. 
  

	9.	Orders and Forecasts  

 9.1 First Year Estimate. Seattle Genetics shall, within
one hundred twenty (120) days after filing its BLA for Bulk Drug Substance, provide Abbott with a written estimate of Seattle Genetics’ monthly requirements of Bulk Drug Substance to be supplied by Abbott for the first Contract Year;
provided, however, the Parties acknowledge that most if not all requirements of Bulk Drug Substance for the first Contract Year may be obtained through the validation runs described in Stage IV of the Project. Abbott acknowledges that such
quantities are estimates only and are nonbinding. 
 9.2 First Order. Abbott and Seattle Genetics shall cooperate fully in estimating
and scheduling production for Seattle Genetics’ first commercial order of Bulk Drug Substance in anticipation of regulatory approval of Bulk Drug Substance. 

9.3 First Firm Order. Approximately six (6) months in advance (the “Initial Order Date”) of the desired Bulk Drug
Substance availability date, Seattle Genetics shall place its first firm Purchase Order for a period of time equal to the longer of (a) the remaining months of the calendar year in which the Initial Order Date occurs or (b) six months
following the Initial Order Date. At the same time, Seattle Genetics shall provide to Abbott Seattle Genetics’ estimate of its monthly requirements of Bulk Drug Substance to be supplied by Abbott for the next succeeding twelve
(12) calendar month period. For illustrative purposes only, the following are examples of how the Parties intend to apply this Section 9.3: 

Example 1: If the desired Bulk Drug Substance availability date is May 15, 2005, Seattle Genetics will place its first firm
Purchase Order on the Initial Order Date (which will be November 15, 2004) for its expected orders to be delivered during the period of time of May 15 - December 31, 2005. 

Example 2: If the desired Bulk Drug Substance availability date is October 15, 2005, Seattle Genetics will place its first firm
Purchase Order on the Initial Order Date (which will be May 15, 2005) for its expected orders to be delivered during the period of time of October 15, 2005 - April 15, 2006. 

 9.4 Rolling Forecast. At the beginning of each Calendar Quarter following the Initial
Order Date, Seattle Genetics shall provide to Abbott a rolling eighteen (18) month projection of requirements of Bulk Drug Substance to be supplied by Abbott, with the first six (6) months of such projection consisting of firm Purchase
Orders and the remaining twelve (12) months of such projection consisting of Seattle Genetics’ best estimate forecast of its Bulk Drug Substance requirements (the “Rolling Forecast”). For illustrative purposes only, the following
are examples of how the Parties intend to apply this Section 9.4: 
 Example 1: Considering the scenario under Example 1 of
Section 9.3, at the beginning of each Calendar Quarter following the Initial Order Date, commencing the first Calendar Quarter (January - March) of 2005, Seattle Genetics shall provide to Abbott a rolling eighteen (18) month forecast in
the format described above; provided, however, the Parties recognize that all months from May 15 - December 31, 2005 will remain firm due to the initial firm forecast produced under Section 9.3. 

Example 2: Considering the scenario under Example 2 of Section 9.3, at the beginning of each Calendar Quarter following the Initial
Order Date, commencing the third Calendar Quarter (July - September) 2005, Seattle Genetics shall provide to Abbott a rolling eighteen (18) month forecast in the format described above; provided, however, the Parties recognize that all months
from October 15, 2005 - April 15, 2006 will remain firm due to the initial firm forecast produced under Section 9.3. 
 9.5
Purchase Order Acceptance. If a firm Purchase Order is not in excess of one hundred twenty percent (120%) of the amounts previously reflected for the applicable months in the immediately preceding Rolling Forecast, and the amounts in the
firm Purchase Order are in compliance with the Maximum Quarterly Capacity, the firm Purchase Order shall be deemed accepted by Abbott upon its receipt thereof. If, however, the firm Purchase Order exceeds such one hundred twenty percent (120%), or
the amounts ordered for any given Calendar Quarter would exceed the Maximum Quarterly Capacity, then, within thirty (30) days after receipt of Seattle Genetics’ firm Purchase Orders for Bulk Drug Substance, Abbott shall confirm to Seattle
Genetics its acceptance or non acceptance of the Purchase Order, the delivery date and the quantity of Bulk Drug Substance ordered by Seattle Genetics, however, the Parties acknowledge that a firm Purchase Order may be in excess of one hundred
twenty percent (120%) or exceed the Calendar Quarter Maximum Quarterly Capacity during the twelve (12) month time period immediately preceding the anticipated First Commercial Sale. During such time period, Abbott shall use commercially
reasonable efforts to accept the firm Purchase Order in excess of one hundred twenty percent (120%) or the Calendar Quarter Maximum Quarterly Capacity. In the event that Abbott is unable to meet Seattle Genetics’ order, then Seattle
Genetics may either (a) reduce its firm Purchase Order to no more than one hundred twenty percent (120%) of the amounts previously reflected for the applicable months in the Rolling Forecast and to fall into compliance with the Maximum
Quarterly Capacity or (b) employ a Third Party supplier of Bulk Drug Substance, provided that the Third Party supplier is only employed to supply the firm Purchase Order for which Abbott was unable to fulfill. 

 9.6 Firm Order Changes. If, due to significant unforeseen circumstances, Seattle Genetics
requests to increase Seattle Genetics’ firm Purchase Order within the six (6) month firm Purchase Order timeframe, then Abbott shall attempt to accommodate the changes within reasonable manufacturing capabilities and efficiencies. Abbott
shall advise Seattle Genetics in writing of the costs associated with making any such change and Seattle Genetics shall be deemed to have accepted the obligation to pay Abbott for such costs if Seattle Genetics indicates to Abbott, in writing, that
Abbott should proceed to make the change. Abbott is obligated to fill all accepted firm Purchase Orders for Bulk Drug Substance provided that (i) the Purchase Order is no greater than one hundred twenty percent (120%) of the amounts
previously reflected for the applicable months in the immediately preceding Rolling Forecast and (ii) the firm Purchase Order is in compliance with the Maximum Quarterly Capacity. Abbott shall use reasonable commercial efforts to fill any
accepted firm Purchase Orders for Bulk Drug Substance in excess of such one hundred twenty percent (120%). 
 9.7 Purchase Order
Terms. Each Purchase Order or any acknowledgment thereof, whether printed, stamped, typed, or written shall be governed by the terms of this Agreement and none of the provisions of such Purchase Order or acknowledgment shall be applicable except
those specifying Bulk Drug Substance and quantity ordered, delivery dates, special shipping instructions and invoice information. 
 9.8
Acceptance of Bulk Drug Substance. 
 (a) Acceptance. Seattle Genetics shall inspect the Bulk Drug Substance manufactured by
Abbott following receipt thereof and, within forty-five (45) days following receipt of the items to be delivered pursuant to Section 8.1, (i) shall give Abbott written notice (a “Deficiency Notice”) of any Bulk Drug
Substance that fails to comply with any of Abbott’s warranties stated in Section 13.2; and (ii) shall reconcile the shipment against the relevant firm Purchase Order and give Abbott notice of any shortages. Should Seattle Genetics
fail to provide Abbott with written notice of its acceptance or rejection of the Bulk Drug Substance within the above described forty-five (45) day period, then the delivery shall be deemed to have been accepted by Seattle Genetics on the
forty-sixth (46th) day after delivery of the items required pursuant to Section 8.1, except with respect to defects or items of nonconformance which could not be discovered at such time
in the exercise of reasonable care, provided that in regard to any such non-discoverable defects, Seattle Genetics shall notify Abbott of such defects prior to eight (8) months after acceptance of such Bulk Drug Substance in accordance with
this Section 9.8(a). In the event that Seattle Genetics does not provide notice regarding non-discoverable defects within such eight (8) month time period, then Seattle Genetics shall be deemed to have accepted such Bulk Drug Substance.
Any written notice to Abbott of its failure to deliver an item required to be delivered pursuant to Section 8.1 or of a shortage of greater than twenty percent (20%) of Bulk Drug Substance, as required to be delivered by Abbott in
accordance with Section 9.5 shall be deemed to be a Deficiency Notice. 
 (b) Determination of Deficiency. Upon receipt of a
Deficiency Notice pertaining to compliance with the Bulk Drug Substance Specifications, Abbott shall have forty-five (45) days to advise Seattle Genetics in writing that it agrees or disagrees in good faith with the contents of such Deficiency
Notice (the “Response Notice”). If Seattle Genetics and Abbott fail to agree within forty-five (45) days after Seattle Genetics’ 

 
receipt of Abbott’s Response Notice, then the Parties shall promptly mutually select an independent laboratory to evaluate (using the test methods described in the Bulk Drug Substance
Specifications) if the Bulk Drug Substance deviates from any Bulk Drug Substance Specifications. Such evaluation shall be binding on the Parties, and if such evaluation certifies that the Bulk Drug Substance deviates from any Bulk Drug Substance
Specifications, Seattle Genetics may reject that Bulk Drug Substance in accordance with Section 9.8(c). If such evaluation reveals that the Bulk Drug Substance in question complies with the Bulk Drug Substance Specifications and Abbott has
complied with all the warranties in Section 13.2, then Seattle Genetics shall be deemed to have accepted delivery of such Bulk Drug Substance upon the independent laboratory issuing its opinion. If the Bulk Drug Substance is found to be in
compliance with the Bulk Drug Substance Specifications, Seattle Genetics shall pay the costs of the independent laboratory. Otherwise, Abbott shall pay such costs. 

(c) Rejection. Subject to the provisions of Section 9.8(b), Seattle Genetics has the right to reject and return, at the expense of
Abbott, any portion of any shipment of Bulk Drug Substance that deviates from any Bulk Drug Substance Specifications, without invalidating any remainder of such shipment, to the extent that such deviation arises from Abbott’s failure to
manufacture and supply the Bulk Drug Substance in accordance with this Agreement (including, without limitation, the Bulk Drug Substance Specifications). In such event, Abbott at its cost shall promptly replace such rejected amounts with Bulk
Drug Substance that conforms with the Bulk Drug Substance Specifications. 
  

	10.	Proprietary Ownership of Development Work, Preexisting Technology and License Grants 

10.1 Existing Proprietary Information. Except as otherwise expressly provided herein, neither Party shall be deemed to have been granted
any license or other rights to patent rights, know-how relating to compounds, formulations, or processes which are owned or controlled by the other Party existing as of the Effective Date. 

10.2 Abbott Inventions. Abbott shall own all proprietary rights to Abbott Inventions, and may obtain patent, copyright, and/or other
proprietary protection relating thereto. Abbott hereby grants to Seattle Genetics an irrevocable, worldwide, nonexclusive license with the right to grant sublicenses, to each Abbott Invention which has been incorporated into the manufacturing
process of the Bulk Drug Substance. Use of such license shall bear a royalty equal to five percent (5%) of the Applicable Dollar Volume, but only in the event that Abbott Patent Rights essential for the manufacture of Bulk Drug Substance are
included in such license. The obligation to pay such royalty shall expire upon the earlier of (i) the last to expire issued claim contained with such licensed Abbott Patent Rights or (ii) ten (10) years. Prior to incorporating any
Abbott Invention into the manufacturing process for the Bulk Drug Substance that will require the payment of such a royalty to Abbott in the future, Abbott shall (1) provide Seattle Genetics with all reasonably necessary information regarding
the Abbott Invention (provided that such information is within Abbott’s control and such disclosure is not prohibited or restricted by confidentiality protections, in which event, Abbott shall use reasonable efforts to obtain appropriate
waivers to permit disclosure of such information) to allow Seattle Genetics to conduct intellectual property due diligence, including without limitation all relevant patents, patent application, patent file wrappers, any

 
validity or patentability searches or opinions and any applicable license agreements and (2) obtain Seattle Genetics prior written approval for inclusion of such Abbott Invention. In the
event that either (x) Abbott incorporates such Abbott Invention without Seattle Genetics’ approval or (y) Seattle Genetics requires such license because Abbott cannot supply Bulk Drug substance in accordance with the requirements of
the Agreement and such failure is not the result of Seattle Genetics actions or negligence, then during such period of time when Abbott fails to supply Seattle Genetics or during the time when Abbott incorporates such Abbott Invention without
Seattle Genetics’ approval, Seattle Genetics shall have a royalty free non-exclusive license in accordance with this Section 10.2. “Applicable Dollar Volume” shall mean, as applicable, either (a) the purchase price paid by
Seattle Genetics or its Third Party licensee for their purchase of Bulk Drug Substance from a Third Party manufacturer that is utilizing such licensed Abbott Inventions solely for the manufacturer of Bulk Drug Substance; or (b) one hundred
twenty five percent (125%) of the actual Fully Burdened Manufacturing Cost of the Bulk Drug Substance incurred by Seattle Genetics or its Third Party Licensee to manufacture such Bulk Drug Substance internally utilizing such Abbott Invention.
In the event that Abbott files a patent application on an Abbott Invention, then Abbott shall so notify Seattle Genetics within thirty (30) days of the filing of such patent application. 

10.3 Seattle Genetics Inventions. With respect to any ideas, innovations or inventions (whether or not patentable) developed by Seattle
Genetics (alone, or in conjunction with Third Parties) during the Term and relating to the Bulk Drug Substance, other than Abbott Inventions (“Seattle Genetics Inventions”), Seattle Genetics shall own all proprietary rights to such Seattle
Genetics Inventions, and may obtain patent, copyright, and/or other proprietary protection relating to such ideas, innovations and inventions. Abbott hereby assigns and shall assign to Seattle Genetics all of Abbott’s right, title and interest
in and to the Seattle Genetics’ Inventions. During the Term, Seattle Genetics hereby grants to Abbott a royalty-free, worldwide, nonexclusive license (with the right to grant sublicenses upon Seattle
Genetics written approval in each case) for the sole purpose of satisfying Abbott’s obligations hereunder, to Seattle Genetics Confidential Information, Seattle Genetics Know-How, Seattle Genetics Patent
Rights, Seattle Genetics Inventions and other proprietary rights reasonably necessary to conduct the research and development work described in Articles 3 and 4 hereof, and to comply with Abbott’s obligations hereunder, including without
limitation, making and supplying to Seattle Genetics Bulk Drug Substance hereunder. 
 10.4 Joint Inventions. Except for inventions
to be owned individually by a Party as described in Sections 10.2 and 10.3 above, each Party shall own a fifty percent (50%) undivided interest in all such inventions, discoveries and know-how made,
conceived, reduced to practice and/or otherwise generated jointly by at least one employee, agent, or other person acting for each Party in the course of this Agreement. The Parties shall collaborate on any actions with respect to the protection of
their joint rights in such inventions, discoveries and know-how, at shared expense, and thereafter each Party may make, use, sell, keep, license, assign, or mortgage such
jointly-owned inventions, discoveries and know-how, and otherwise undertake all activities a sole owner might undertake with respect to such inventions, discoveries and know-how, with the prior written consent of the other Party, which consent shall not be unreasonably withheld. 

	11.	Confidential Information 

 Neither Party shall use or disclose any of the other
Party’s Confidential Information received by it without the prior written consent of the other Party. Except as provided in the following sentence, nothing contained in this Article shall be construed to restrict the Parties from disclosing
Confidential Information as is reasonably necessary to perform acts expressly permitted by this Agreement or such acts the Parties’ could reasonably expect to be performed in conjunction with the approval and/or manufacture of Bulk Drug
Substance and/or any Product. However, if either Party is required or feels it necessary to disclose any of the other Party’s Confidential Information received by it pursuant to this Agreement (whether by audit or otherwise) to any Third Party
or governmental authority or agency in compliance with any federal, state and/or local laws and/or regulations, or pursuant to an order of a court of competent jurisdiction, the disclosing Party shall first notify the Party owning such Confidential
Information, prior to any such disclosure, in order to afford the disclosing Party a reasonable opportunity to obtain a protective order as to such information and will use reasonable efforts to obtain reliable assurance that the information
disclosed will be treated confidentially. In any event, each Party shall make any disclosures of the other Party’s Confidential Information received by it pursuant to this Agreement only to the extent required, and only to such persons who have
a need to know. The obligations of each Party relating to the other Party’s Confidential Information shall expire ten (10) years after termination of this Agreement. The disclosure of Confidential Information shall not constitute the grant
of any license or any other rights, or generate any business arrangements, unless specifically set forth herein or in another writing. 

Neither Party shall disclose the existence or any terms and conditions of this Agreement except (a) with the other Party’s prior
written consent or (b) as required to comply with foreign, federal, state or local laws and regulations (including, without limitation, federal and state securities laws and regulations). 

Each Party acknowledges that the remedy at law for any breach of this Article 11 would be inadequate, and the full amount of damages that may
result from such breach is not readily susceptible to being measured in monetary terms. Accordingly, in the event of a breach or threatened breach by either Party of this Article 11, the other Party shall be entitled to immediate injunctive relief
prohibiting any such breach and requiring the immediate return of all Confidential Information. Such remedies shall be in addition to any other remedies that may be available. 

 

	12.	Term and Termination 

 12.1 Term. This Agreement shall become effective as of the
Effective Date, and unless sooner terminated hereunder, shall continue in effect until the completion of the tenth (10th) Contract Year following the Launch Date (the “Term”). AT
THE END OF THE TERM, THE TERM SHALL BE EXTENDED AND, UNLESS SOONER TERMINATED HEREUNDER, SHALL TERMINATE ONLY AFTER NO LESS THAN EIGHTEEN (18) MONTHS’ PRIOR WRITTEN NOTICE OF A PARTY’S INTENT TO TERMINATE IS GIVEN TO THE OTHER PARTY
(WHICH NOTICE MAY BE GIVEN PRIOR TO OR AFTER THE EXPIRATION OF THE INITIAL TERM). 

 12.2 Seattle Genetics Termination Rights. Seattle Genetics may terminate the
Project (i) upon one (1) year prior written notice to Abbott if Seattle Genetics determines in good faith that the clinical, development and/or commercial stage of the Bulk Drug Substance, before or after the Launch Date, is not
technically, clinically or commercially feasible as determined by Seattle Genetics, (ii) upon thirty (30) days’ prior written notice to Abbott, in the event Seattle Genetics delivers to Abbott three (3) or more Deficiency Notices
in any twelve (12) month period or Deficiency Notices in respect of two consecutive shipments, (iii) immediately after prior written notice to Abbott in accordance with Section 2.2 or (iv) in accordance with Sections 7.1 or 7.5
after prior written notice in accordance with such Sections. In the event that Seattle Genetics, its Affiliates or its Third Party licensees begins commercial development and sale of the Bulk Drug Substance within twelve (12) months of
termination of this Agreement in accordance with clause (i) of this Section, then Abbott shall have the option of reinstating this Agreement and Seattle Genetics shall be obligated to purchase the Bulk Drug Substance from Abbott, provided that
Seattle Genetics’ prior termination of this Agreement was not related to any deficiency uniquely related to Abbott’s facility or performance, including without limitation problems with process development, scale-up, Bulk Drug Substance
quality, regulatory issues or timing delays. 
 12.3 Abbott Termination Rights. Abbott may terminate this Agreement (i) upon one
(1) year prior written notice to Seattle Genetics if Abbott determines in good faith that the development of a commercially reasonable manufacturing process for the Bulk Drug Substance, is not technically or operationally feasible in
Abbott’s Worcester, Massachusetts facility, or other alternative facilities as identified by Abbott or (ii) immediately after prior written notice to Seattle Genetics in accordance with Sections 2.2 and 7.5. 

12.4 General Termination Rights. Upon the occurrence of the following events, either Party may terminate this Agreement by giving the
other Party sixty (60) days prior written notice: 
  

	 	(a)	Upon the bankruptcy or insolvency of the other Party; 

  

	 	(b)	Upon the material breach of any provision of this Agreement by the other Party if the breach is not remedied prior to the expiration of such sixty (60)-day notice period, or if
the breach is of a type that cannot be remedied within sixty (60) days, then a remedy promptly commenced and diligently pursued until complete remediation; or 

 

	 	(c)	Upon the breach of the representations and warranties contained in Section 28. 

 12.5
Termination in Event of Hardship. In the event that during the Term the general situation and/or the data and/or economic appropriateness on which this Agreement is based are substantially changed such that it is not commercially reasonable
for a Party to proceed towards commercialization of the Bulk Drug Substance, such Party may, after good faith negotiations between the Parties, terminate this Agreement with sixty (60) days’ prior written notice to the other Party;
provided, however, that in the event that Seattle Genetics, its Affiliates or its Third Party licensees subsequently proceeds toward the commercialization of Bulk Drug Substance, within twelve (12) months of termination of this Agreement in
accordance with this Section, then Abbott shall have the option of reinstating this Agreement and Seattle Genetics shall be obligated to purchase the Bulk Drug Substance from Abbott, provided that Seattle Genetics’ prior termination of this
Agreement was not related to any deficiency uniquely related to Abbott’s facility or performance, including without limitation problems with process development, scale-up, Bulk Drug Substance quality, regulatory issues or timing delays. 

 12.6 Termination Due to Regulatory Action. Seattle Genetics may terminate this Agreement
upon thirty (30) days’ written notice in the event that a Regulatory Authority takes any action, lasting more than six (6) months, directly affecting Abbott’s ability to operate its biologics manufacturing business or the
manufacturing facilities at which the Bulk Drug Substance is being made. Abbott shall take reasonable steps to achieve the orderly transition of the manufacturing process to a Third Party and shall pay all costs payable to said Third Party (other
than Affiliates of either Party) (less any costs recoverable by Seattle Genetics in the form of Bulk Drug Substance that may be incorporated into marketable Product) to complete a BLA with respect to the replacement manufacturer’s production of
the Bulk Drug Substance provided that Abbott’s share of such costs shall not exceed Three Million Seven Hundred Fifty Thousand Dollars (U.S. $3,750,000). Seattle Genetics shall ensure that the Third Party manufacturer shall be subject to terms
of confidentiality with respect to Abbott’s Confidential Information, as well as this Section 12.6, that are no less protective than the confidentiality set forth in Article 11 of this Agreement. 

12.7 Actions on Termination. Upon expiration or termination of this Agreement for any reason, the following shall occur: 

(a) Dedicated Equipment. In accordance with Section 8.8, upon Seattle Genetics’ option (i) Abbott shall deliver to
Seattle Genetics (at Seattle Genetics’ cost of removal and shipment) all Dedicated Equipment or if the Parties mutually agree (ii) Abbott shall purchase all Dedicated Equipment from Seattle Genetics at its depreciated (calculated on a
straight-line basis) book value thereof; 
 (b) Confidential Information and Records. Subject to Section 12.7(c), each Party
shall deliver to the other, or destroy at the Parties election, all materials, reports, and other documents (including copies thereof) in its possession or control containing Confidential Information of the other Party, and each will cease to make
use of the other’s Confidential Information; in particular, the Bulk Drug Substance Specifications shall be promptly returned to Seattle Genetics along with the following records, which are to be maintained by Abbott on behalf of Seattle
Genetics during the Term: Bulk Drug Substance Specific Master Manufacturing Batch Records; Drug Product Specific Test Methods; Drug Product Specific Standard Operating Procedures; Drug Product Specific Material Specifications (in-process limits and
Drug Product specifications); and Drug Product Specific Validation Protocols and Reports (Equipment, Process, Cleaning, Test Method); 
 (c)
Technology Transfer. Upon Seattle Genetics’ request and provided that the Agreement neither (i) was terminated by Abbott in accordance with Section 12.4 nor (ii) has expired or terminated in accordance with
Section 12.1, Abbott will reasonably assist Seattle Genetics with the transfer of the manufacturing process associated with the Bulk Drug Substance to Seattle Genetics or its designee (in the event that the Agreement was terminated by Abbott in
accordance with Section 12.4 or has expired or terminated in accordance with Section 12.1, Seattle Genetics shall have the option to have Abbott reasonably assist Seattle Genetics with the transfer of the manufacturing process associated
with the Bulk Drug Substance to Seattle Genetics or its designee, at Seattle Genetics sole cost and expense); 

 (d) Raw Materials. Abbott shall return to Seattle Genetics all unused raw materials
associated with Bulk Drug Substance to the extent it has been paid for by Seattle Genetics; 
 (e) Maintenance of Information. Abbott
and Seattle Genetics shall continue to maintain information about the Bulk Drug Substance and its production for such time and in such manner as required by the Regulatory Authorities and shall continue to respond in a timely manner to all queries
and requests for information from Regulatory Authorities; and 
 (f) Project Reassignment Costs. If the Project is terminated, Abbott
shall advise Seattle Genetics of Abbott’s reasonable research and development fees on the Project incurred in accordance with the Project budget as described in Article 5 of this Agreement (“Incurred Fees”) prior to such termination.
The Parties shall negotiate in good faith an appropriate and reasonable adjustment based upon Abbott’s Incurred Fees and Seattle Genetics’ Research and Development Fee payments previously made following such termination. Unless the
Agreement was terminated in accordance with Section 12.4(b) due to Abbott’s material breach, Seattle Genetics shall pay Abbott for reasonable documented costs associated with reassignment of resources as determined in good faith by Abbott
(“Reassignment Costs”). Such Reassignment Costs shall include but not be limited to: analytical labor and assets; development labor and assets; manufacturing labor and assets; and testing labor and assets (less any avoidable out-of-pocket
costs). Abbott shall use reasonable efforts to minimize Reassignment Costs. Any such Reassignment Costs shall be limited to costs incurred within the period of time that is the shorter of (a) actual reassignment of the labor, assets and other
resources or (b) the sixty (60) day period following the termination of the Agreement, except to the extent that Seattle Genetics approves such additional costs in writing. Abbott shall provide to Seattle Genetics a detailed summary of
Incurred Fees and Reassignment Costs payable pursuant to this Section 12.7. 
 12.8 Purchase of Firm Orders. Upon termination of
this Agreement by Seattle Genetics for any reason, except for Abbott’s material breach in accordance with Section 12.4(b), Seattle Genetics shall pay an amount to Abbott equal to the then outstanding, firm Purchase Order (as described in
Section 9.4). Notwithstanding the foregoing, if Abbott is able to resell its unused capacity that was attributable to the firm Purchase Order, it shall provide Seattle Genetics with a reasonable credit, offset or refund (as elected by Seattle
Genetics) in an amount to be determined in good faith by Abbott. Seattle Genetics shall have no purchase obligations beyond the amounts reflected in the firm Purchase Order. 

12.9 Survival Provisions. Termination, expiration, cancellation or abandonment of this Agreement through any means and for any reason
shall not relieve the Parties of any obligation accruing prior thereto, including, but not limited to, the obligation to pay money, and shall be without prejudice to the rights and remedies of either Party with respect to the antecedent breach of
any of the provisions of this Agreement. Further, Articles 1, 10-16, 18-21, and 24 and Sections 2.3 (Payment for Reserved Capacity), 5.3, 8.6, 8.8, 9.3 and 9.4 (firm orders), shall survive the termination of this Agreement. 

	13.	Warranties 

 13.1 Seattle Genetics Warranties. Seattle Genetics warrants that it
owns or controls all of the rights in and to the Seattle Genetics Patent Rights, Seattle Genetics Know-How, and Confidential Information provided by Seattle Genetics to Abbott hereunder, and that it has the
full right and authority to grant to Abbott the licenses described in Section 10.3. SEATTLE GENETICS MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO BULK DRUG SUBSTANCE, SEATTLE GENETICS PATENT RIGHTS, SEATTLE GENETICS KNOW-HOW,
AND SEATTLE GENETICS CONFIDENTIAL INFORMATION PROVIDED HEREUNDER. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT, ARE HEREBY
DISCLAIMED BY SEATTLE GENETICS. IN NO EVENT SHALL SEATTLE GENETICS OR SEATTLE GENETICS’ AFFILIATES BE LIABLE FOR INDIRECT, INCIDENTAL, LIQUIDATED OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST REVENUES OR PROFITS. If at any time
any representation or warranty to Seattle Genetics’ knowledge is no longer accurate, Seattle Genetics will promptly notify Abbott of such fact. 

13.2 Abbott Warranties. Abbott warrants to Seattle Genetics that Bulk Drug Substance delivered to Seattle Genetics pursuant to this
Agreement (other than pursuant to Section 6.1) shall have been manufactured pursuant to cGMPs, the Batch Records shall conform with the Bulk Drug Substance Specifications, shall have been manufactured in compliance with this Agreement and all
applicable laws and regulations and shall be free from defects in materials and workmanship. Abbott warrants to Seattle Genetics that it has, and shall maintain in compliance with applicable laws and regulations during the Term, the facilities,
equipment, personnel, licenses and patents and expertise necessary to fulfill its obligations hereunder. Abbott also represents and warrants that (a) it is not debarred and has not and will not knowingly use in any capacity the services of any
person debarred under Section 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992 as amended or any comparable law of the EMEA or any ICH confirming country, as each may be amended from time to time, and (b) the Bulk
Drug Product will not be adulterated or misbranded, within the meaning of the U.S. Food, Drug & Cosmetics Act, or any comparable laws, rules or regulations of any non-U.S. jurisdiction, as a result of any act or omission of Abbott. In
addition, if any Abbott Inventions are incorporated into the manufacturing process of the Bulk Drug Substance, without Abbott obtaining Seattle Genetics’ written consent, Abbott warrants that, to Abbott’s knowledge, Seattle Genetics’
use of such Abbott Inventions shall not infringe or conflict with any patent or other proprietary right of any Third Party and there is no claim or basis therefor that might impair the use of such Abbott Inventions by Seattle Genetics to manufacture
Bulk Drug Substance. ABBOTT MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO BULK DRUG SUBSTANCE. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT, ARE HEREBY DISCLAIMED BY ABBOTT. NOTWITHSTANDING ANY PROVISION TO THE 

 
CONTRARY IN THIS AGREEMENT, IN NO EVENT SHALL ABBOTT OR ABBOTT’S AFFILIATES BE LIABLE FOR INDIRECT, INCIDENTAL, LIQUIDATED OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST
REVENUES OR PROFITS. If at any time any representation or warranty to Abbott’s knowledge is no longer accurate, Abbott will promptly notify Seattle Genetics of such fact. 

 

	14.	Indemnification 

 14.1 Seattle Genetics Indemnification. Seattle Genetics shall
defend, indemnify and hold harmless Abbott, its Affiliates, and its permitted contractors and their respective employees, directors and agents against any Liability resulting from any Third Party demand or lawsuit arising from (i) Seattle
Genetics’ negligence or willful misconduct in the development, testing, use, manufacture, promotion, marketing, sale, distribution, packaging, labeling, handling, storage, and/or disposal of Bulk Drug Substance and/or formulations containing
Bulk Drug Substance; or (ii) alleged infringement of any patent or other proprietary rights of such Third Party based on the testing, use, manufacture, promotion, marketing, sale, distribution, packaging, labeling, handling, storage, and/or
disposal of the Bulk Drug Substance by Abbott, its Affiliates, and permitted contractors, except to the extent the Third Party demands, or lawsuit arises predominantly out of, or relates to the events described in Section 14.2 (ii); or
(iii) Seattle Genetics’ and/or any Seattle Genetics’ Affiliate’s, licensee’s and/or sublicensee’s material breach of this Agreement, except to the extent the Third Party demand or lawsuit arises predominantly out of or
relates to the events described in Section 14.2. 
 14.2 Abbott Indemnification. Abbott shall defend, indemnify and hold
harmless Seattle Genetics, its Affiliates, licensees and sublicensees and their respective employees, directors and agents against any Liability arising from (i) Abbott’s negligence or willful misconduct in the development, testing, use,
storage, handling, packaging, labeling, manufacture, storage or delivery of Bulk Drug Substance, formulations containing Bulk Drug Substance or its raw materials; (ii) a demand, claim or action brought by a Third Party based on any
manufacturing procedures, methods or techniques (or component thereof) that are incorporated into the manufacturing process of the Bulk Drug Substance by Abbott which Seattle Genetics did not provide written consent and are other than Seattle
Genetics Patent Rights, Seattle Genetics Know-How and Seattle Genetics Inventions, or (iii) Abbott’s, its Affiliate’s, or its contractor’s material breach of this Agreement, except to the extent the Third Party demand or lawsuit
arises predominantly out of or relates to the events described in Section 14.1. 
 14.3 Claims and Proceedings. Each Party shall
notify the other promptly of any threatened or pending claim or proceeding covered by any of the above Sections in this Article 14 and shall include sufficient information to enable the other Party to assess the facts; provided, however, the failure
to provide such notice within a reasonable period of time shall not relieve the indemnifying Party of its obligations hereunder except to the extent the it is prejudiced by such failure. Each Party shall cooperate in good faith with the indemnifying
Party in the defense of all such claims, with the indemnifying Party being permitted to maintain control of such defense through legal counsel selected by such Party. No settlement or compromise shall be binding on a Party hereto without its prior
written consent. 

	15.	Assignment 

 Neither Party may assign this Agreement or any of its rights under this
Agreement or delegate (or subcontract) any of its duties or obligations under this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the
foregoing, but subject to the last sentence of this Article 15, either Party may assign this Agreement, without the other Party’s consent, to any purchaser of all or substantially all of such Party’s assets, or to any successor by way of
merger, consolidation or similar transaction. Subject to the foregoing, this Agreement will be binding upon, enforceable by, and inure to the benefit of the Parties and their respective successors and assigns. It shall be deemed reasonable to
withhold consent to an assignment of this Agreement in the event that such assignment would materially impair or jeopardize any pending or actual regulatory approval for the manufacture of the Bulk Drug Substance or adversely affect the regulatory
status of the Bulk Drug Substance or any Product. It shall be deemed reasonable for Seattle Genetics to withhold consent to an assignment in the event that such assignment would have a substantial likelihood of (a) impairing or jeopardizing any
pending or actual regulatory approval for the manufacture of the Bulk Drug Substance, (b) adversely affecting the regulatory status of the Bulk Drug Substance or (c) materially delaying delivery schedules, increasing the pricing or
adversely affecting the quality of the Bulk Drug Substance. 
  

	16.	Notices 

 All notices hereunder shall be in writing and shall be delivered personally, by
nationally recognized courier service, registered or certified mail, postage prepaid, mailed by express mail service or given by facsimile (with hard copy sent by one of the other approved methods on the same day), to the following addresses of the
respective Parties: 
  

			
	If to Abbott:		Abbott Laboratories
			Senior Vice President,
			Global Pharmaceutical Manufacturing
			Department 390, Building NCA1
			1401 Sheridan Road
			North Chicago, IL 60064-6314
			Fax Number: 847-938-2315

  

			
	with copy to:		Abbott Laboratories
			Senior Vice President and General Counsel
			Department 364, Building AP6D
			100 Abbott Park Road
			Abbott Park, IL 60064-6049
			Fax Number: 847-938-6277

  

			
	If to Seattle Genetics:		Seattle Genetics, Inc.
			Chief Executive Officer
			21823 30th Drive SE
			Bothell, WA 98021
			Fax Number: (425) 527-4109

			
	with copy to:		Seattle Genetics, Inc.
			General Counsel
			21823 30th Drive SE
			Bothell, WA 98021
			Fax Number: (425) 527-4109

 Notices shall be effective upon receipt if personally delivered, on the third business day following the date of mailing if
sent by certified or registered mail, and on the second business day following the date of delivery to the express mail service if sent by express mail, or the date of transmission if sent by facsimile (provided a hard copy is sent as described
above). A Party may change its address listed above by notice to the other Party. 
  

	17.	Entire Agreement; Amendments 

 This Agreement constitutes the entire agreement between
the Parties concerning the subject matter hereof and supersedes all written or oral prior agreements or understandings with respect thereto, including, without limitation, that certain Material Transfer Agreement dated December 15, 2003 between
Abbott and Seattle Genetics. No amendment or modification to this Agreement will be effective unless it is in writing and signed by both Parties to this Agreement. 
  

	18.	Alternative Dispute Resolution and Applicable Law 

 18.1 Choice of Law. This
Agreement shall be construed, interpreted and governed by the laws of the State of Illinois, excluding its choice of law provisions. 
 18.2
Alternative Dispute Resolution. The Parties recognize that bona fide disputes may arise which relate to the Parties’ rights and obligations under this Agreement. The Parties agree that any such dispute shall be resolved by Alternative
Dispute Resolution (“ADR”) in accordance with the procedure set forth in Exhibit E. 
  

	19.	Force Majeure 

 Any delay in the performance of any of the duties or obligations of any
Party (except the payment of money due hereunder for services rendered) caused by an event outside the affected Party’s reasonable control shall not be considered a breach of this Agreement, and unless provided to the contrary herein, the time
required for performance shall be extended for a period equal to the period of such delay. Such events shall include without limitation, acts of God; acts of the public enemy; insurrections; riots; terrorism, injunctions; embargoes; labor disputes,
including strikes, lockouts, job actions, or boycotts; fires; explosions; floods; earthquakes; shortages of material or energy; delays in the delivery of raw materials, or other unforeseeable causes beyond the reasonable control and without the
fault or negligence of the Party so affected (a “Force Majeure Event”). The Party so affected shall give prompt notice to the other Party of such cause, following which the Parties will promptly meet to determine an equitable solution to
the effects of such event and the Party affected by the event shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. Seattle Genetics may cancel without penalty (and shall have no

 
obligation to pay any amounts attributable to minimum quantities or firm Purchase Orders applicable to any period following the date of the Force Majeure Event) (a) any and all Purchase
Orders in the event Abbott is unable to fulfill an outstanding Purchase Order within sixty (60) days of its scheduled delivery date due to a Force Majeure Event and (b) this Agreement if the Force Majeure Event affects Abbott’s
ability to perform pursuant to this Agreement for more than an aggregate of one hundred twenty (120) days in any single Contract Year or any consecutive period of ninety (90) days. Upon cessation of such Force Majeure Event, the affected
Party shall promptly resume performance on all Purchase Orders which have not been terminated. 
  

	20.	Severability 

 If any term or provision of this Agreement shall for any reason be held
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and in lieu of each such invalid, illegal or unenforceable provision there shall be added
automatically as a part of this Agreement a provision that is valid, legal and enforceable, and as similar in terms to such invalid, illegal or unenforceable provision as may be possible while giving effect to the benefits and burdens for which the
Parties have bargained hereunder. 
  

	21.	Waiver 

 No waiver or modification of any of the terms of this Agreement shall be valid
unless in writing and signed by an authorized representative of each Party hereto. Failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by either Party in one or
more instances be construed as constituting a continuing waiver or as a waiver in other instances. 
  

	22.	Exhibits 

 All Exhibits referenced herein are hereby made a part of this Agreement. 

 

	23.	Counterparts 

 This Agreement may be executed in any number of separate counterparts,
each of which shall be deemed to be an original, but which together shall constitute one and the same instrument. 
  

	24.	No Publicity 

 Except as required by law or regulation, neither Party shall disclose the
material provisions (as defined in the next sentence) of this Agreement or make any public announcement or public statement concerning the material provisions of this Agreement, without the prior written approval of the other Party. For purposes of
this Article, the term “material provisions” shall include price, term, termination options and ownership of intellectual property. Neither Party shall use the name of the other Party in any publicity release or advertising without the
other Party’s prior written consent, not to be unreasonably withheld. Notwithstanding the foregoing, either Party, without the consent of the other Party, may disclose the general nature and terms of this Agreement to investors or potential
investors, provided that prior to such disclosure, such investors executed confidentiality and non-disclosure agreements with terms no less stringent than as provided for in this Article 24. Any disclosure required by law or judicial order proposed
by a Party that names the other Party, shall first be provided in draft to the other Party. Each Party shall use reasonable best efforts to provide the other Party with ten (10) business days to review such proposed draft. 

	25.	Relationship 

 The relationship between the Parties to this Agreement is that of
independent contractors and nothing herein shall be deemed to constitute the relationship of partners, joint ventures, nor of principal and agent between Abbott and Seattle Genetics. Neither Party shall have any express or implied right or authority
to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract or undertaking with any Third Party. 
  

	26.	Headings 

 The headings in this Agreement are for convenience of reference only and shall
not affect its interpretation. 
  

	27.	Insurance 

 During the Term, Seattle Genetics and Abbott shall maintain in full force and
effect, for the benefit of Seattle Genetics and Abbott respectively product liability insurance (with Abbott’s coverage extending to its obligations as a manufacturer of the Bulk Drug Substance) in an amount of not less than Ten Million Dollars
(U.S.$10,000,000) for each accident or occurrence and in the aggregate. At the inception of this Agreement and annually thereafter, Seattle Genetics and Abbott shall furnish the other with a certificate of insurance evidencing that it has such
insurance coverage in force. During the Term, either Party may self-insure in whole or in part the insurance requirements described above, provided such Party maintains both (a) a net worth as measured by its retained earnings in the amount of
One Hundred Million Dollars (U.S.$100,000,000) and (b) a minimum of Fifteen Million Dollars (U.S. $15,000,000) of unrestricted cash or cash equivalents at its disposal (together, “Self-Insurance Requirement”). If a Party self-insures
in accordance with the foregoing, then in order to be permitted to maintain such self-insurance, such Party must maintain throughout the Term the Self-Insurance Requirement and deliver to other Party, within ninety (90) days after the end of
each of such Party’s fiscal years, a statement in the form described above evidencing the compliance with the Self-Insurance Requirement. If at any time the Party fails to comply with either of the Self-Insurance Requirement, then such Party
must obtain, provide, and keep in full force and effect (until the Party complies with Self-Insurance Requirements) the above referenced insurance coverage and provide the other Party with evidence of the same in accordance with this Section.
Notwithstanding any of the foregoing to the contrary, so long as a Party is publicly traded on a nationally recognized stock exchange, such Party shall have no obligation to provide the other Party with documentation which evidences compliance with
the Self Insurance Requirement as otherwise required pursuant to this Section. 

	28.	Debarment 

 Each of the Parties warrants and represents to the other Party that each such
Party has never been, is not currently, and, during the term of this Agreement, will not become, a Debarred Entity, Excluded Entity or Convicted Entity. Each of the Parties further warrants and represents that no Debarred Individual, Debarred
Entity, Excluded Individual, Excluded Entity, Convicted Individual or Convicted Entity has performed or rendered, or will perform or render, any services or assistance on its behalf relating to activities taken pursuant to this Agreement. If any of
the foregoing warranties or representations becomes untrue as to a specific Party (by way of example only, if Abbott or any individual or entity performing services on its behalf hereunder becomes excluded, debarred or suspended after the Effective
Date of this Agreement), such Party shall immediately notify the other Party and this shall constitute grounds for immediate termination by the Party which has not violated the representations and warranties of this Section. This provision shall
survive termination or expiration of this Agreement. 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized
representatives on the later day and year written below. 
  

									
	ABBOTT LABORATORIES				SEATTLE GENETICS, INC.
					
	By:		/s/ Lance B. Wyatt				By:		/s/ Clay B. Siegall
			Lance B. Wyatt						
	Title:		 Senior Vice President,
 Global Pharmaceutical
Manufacturing
				Title:		President & CEOEX-10.41

 Exhibit 10.41 

EXECUTIVE EMPLOYMENT AGREEMENT 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 17 day of November, 2014, by and between
SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Jean Liu (“Executive”). 
 RECITALS: 

A. The Company desires that Executive perform her services as General Counsel and Executive Vice President, Legal Affairs and
Corporate Secretary of the Company, having been duly appointed to such position by the Board of Directors of the Company. 
 B.
Executive desires to continue in such engagement. 
 C. This Agreement contains other provisions applicable to the employment of
Executive by the Company. 
 In consideration of the above Recitals and the provisions of this Agreement, the Company and Executive agree as
follows: 
 I. DUTIES 
 1.1 Title and
Responsibilities. Executive shall serve as General Counsel and Executive Vice President, Legal Affairs and Corporate Secretary of the Company, which title may be changed at any time in the sole discretion of the Company. Executive’s
responsibilities and duties shall include those inherent in Executive’s position with the Company and shall further include such other managerial responsibilities and executive duties consistent with such position as may be assigned to
Executive from time to time by the Chief Executive Officer of the Company. Executive shall devote her best efforts and full business time to the business and interests of the Company. During the term of Executive’s employment with the Company,
Executive may serve on the board of directors of other companies, manage personal investments, and engage in civic and charitable activities, provided that such activities shall not represent a conflict of interest with the Company and do not
materially detract from fulfilling Executive’s responsibilities and duties to the Company. 
 II. COMPENSATION 

2.1 Base Salary. Executive shall be paid a base salary (“Base Salary”) by the Company during the term of
Executive’s employment at the rate determined by the Compensation Committee of the Board of Directors (the “Compensation Committee”), which is currently $390,000 per year. Executive’s Base Salary shall be reviewed
annually by the Compensation Committee and evaluated based on performance and salary levels of other executives of comparable position within the industry and geographic location of the Company. Based upon such evaluation and review,
Executive’s Base Salary may be adjusted from time to time as determined by the Compensation Committee in its sole discretion. 

 2.2 Bonus. In addition to Base Salary, Executive may be eligible to receive an annual
bonus (“Annual Bonus”), currently targeted at forty-five percent (45%) of Executive’s Base Salary, based upon performance criteria and financial and operational results of the Company as determined by the
Compensation Committee. To the extent that the Annual Bonus is earned and becomes payable in accordance with the terms under which it is offered and unless otherwise specified in a written document reflecting the bonus arrangement, any Annual Bonus
earned by Executive will be paid to Executive prior to two and one half (2  1⁄2) months following the year in which the Annual Bonus becomes payable as a
result of Executive’s vesting in the right to the Annual Bonus. 
 2.3 Stock Options. Executive may be eligible to receive
grants of stock options or purchase rights from time to time in the future, on such terms and subject to such conditions as the Compensation Committee shall determine as of the date of any such grant and pursuant to the existing stock plan(s) of the
Company. 
 2.4 Other Benefits. 

(i) Executive shall be entitled to such employee benefits generally available to full-time salaried employees of the Company, including without
limitation, health insurance, paid vacation of not less than four (4) weeks per year, retirement plans and other similar benefits; provided, that Company reserves the right to amend, modify, terminate or make any other changes in such benefits
generally available to full-time salaried employees of the Company at any time in its sole discretion. 
 (ii) The Company shall pay or
reimburse Executive for all travel and entertainment expenses incurred by Executive in connection with Executive’s duties on behalf of the Company, subject to the reasonable approval of the Company. Executive shall only be entitled to
reimbursement to the extent that Executive follows the reasonable procedures established by the Company for reimbursement of such expenses which will include, but will not be limited to, providing satisfactory evidence of such expenditures. 

III. TERMINATION OF EMPLOYMENT 
 3.1
Termination of Employment and Severance Benefits. 
 (a) Termination of Employment. This Agreement may be terminated upon the
occurrence of any of the following events: 
 (i) The Company’s determination in good faith that it is terminating Executive for Cause
(as defined in Section 3.3 below) (“Termination for Cause”); 
 (ii) The Company’s determination that it is
terminating Executive without Cause, which determination may be made by the Company at any time at the Company’s sole discretion, for any or no reason (“Termination Without Cause”); 

  
 - 2 - 

 (iii) The effective date of a written notice sent to the Company from Executive stating that
Executive is electing to terminate his employment with the Company (“Voluntary Termination”); 
 (iv) A change in
Executive’s status such that a Constructive Termination (as defined in Section 3.2(d) below) has occurred; or 
 (v)
Following Executive’s death or Disability (as defined in Section 3.4 below). 
 3.2 Severance Benefits. Executive
shall be entitled to receive severance benefits upon termination of employment only as set forth in this Section 3.2 contingent upon resignation from all positions held by Executive and only if Executive executes a full release and waiver of
claims within thirty (30) days of Executive’s termination (and allows it to become effective in accordance with its terms): 
 (a)
Voluntary Termination. If Executive’s employment terminates by Voluntary Termination, then Executive shall not be entitled to receive payment of any severance benefits. Executive will receive payment(s) for all salary and unpaid vacation
accrued as of the date of Executive’s termination of employment and Executive’s benefits will be continued under the Company’s then existing benefit plans and policies in accordance with such plans and policies in effect on the date
of termination and in accordance with applicable law. 
 (b) Involuntary Termination. If Executive’s employment is terminated
under Section 3.1(a)(ii) (Termination Without Cause) or 3.1(a)(iv) (Constructive Termination) above (such termination, an “Involuntary Termination”), Executive will be entitled to receive payment of severance benefits equal to
Executive’s regular monthly salary for twelve (12) months (the “Severance Period”). Such payments shall be made, at the Company’s option, in a lump sum within thirty (30) days after the date of Executive’s
Involuntary Termination or periodically over the Severance Period according to the Company’s standard payroll schedule, provided that such payments may not extend beyond two and one-half (2  1⁄2) months following the end of the calendar year in which the date of Involuntary Termination occurs. Executive will also be entitled to receive payment on the date of Involuntary Termination of the pro rata
portion of any Annual Bonus based on achievement of the specific corporate and individual performance targets established for the fiscal year in which the termination occurs, payable prior to two and one-half (2
 1⁄2) months following the end of the calendar year in which the date of Involuntary Termination occurs. Executive will receive payment(s) for all salary and
unpaid vacation accrued as of the date of Executive’s termination of employment and health insurance benefits will be continued through payment of Executive’s COBRA health insurance premiums by the Company over the Severance Period so long
as Executive timely elects to continue Executive’s health insurance coverage under COBRA and subject to COBRA’s terms, conditions and requirements. 

(c) Termination for Cause. If Executive’s employment is terminated for Cause, then Executive shall not be entitled to receive
payment of any severance benefits. Executive will receive payment(s) for all salary and unpaid vacation accrued as of the date of Executive’s termination of employment and Executive’s benefits will be continued under the Company’s
then existing benefit plans and policies in accordance with such plans and policies in effect on the date of termination and in accordance with applicable law. 

  
 - 3 - 

 (d) Constructive Termination. “Constructive Termination” shall be deemed
to occur if (A) there is a material reduction or change in job duties, responsibilities and requirements inconsistent with Executive’s position with the Company and prior duties, responsibilities and requirements, provided that neither a
mere change in title alone nor reassignment to a position that is substantially similar to the position held prior to the change in terms of job duties, responsibilities or requirements shall constitute a material reduction in job responsibilities;
or (B) there is a reduction in Executive’s then-current base salary by at least twenty percent (20%), provided that an across-the-board reduction in the salary level of all other senior executives by the same percentage amount as part of a
general salary level reduction shall not constitute such a salary reduction; or (C) Executive refuses to relocate to a facility or location more than 50 miles from the Company’s current location; provided, however, that in each case above,
Executive must first provide notice of the existence of the circumstances giving rise to a Constructive Termination within ninety (90) days of the initial existence of such circumstances and the Company must be provided with a period of thirty
(30) days from the date of receipt of such notice to cure the circumstances giving rise to a Constructive Termination; provided further that the Company may notify Executive at any time prior to expiration of the cure period that it will not
cure the circumstances, in which case the cure period shall end immediately upon such notification. 
 (e) Termination by Reason of Death
or Disability. In the event that Executive’s employment with the Company terminates as a result of Executive’s death or Disability (as defined in Section 3.4 below), Executive or Executive’s estate or representative
will receive all salary and unpaid vacation accrued as of the date of Executive’s death or Disability and any other benefits payable under the Company’s then existing benefit plans and policies in accordance with such plans and policies in
effect on the date of death or Disability and in accordance with applicable law. In addition, Executive’s estate or representative will receive the amount of Executive’s Annual Bonus for the fiscal year in which the death or Disability
occurs to the extent that the Annual Bonus has been earned as of the date of Executive’s death or Disability, as determined by the Board of Directors or its Compensation Committee based on the specific corporate and individual performance
targets established for such fiscal year, which will be paid prior to two and one-half (2  1⁄2) months following the year of Executive’s death or
Disability (subject to Executive’s termination as a result of such Disability). 
 3.3 Definition of Cause. For purposes of this
Agreement, “Cause” for Executive’s termination will exist at any time after the happening of one or more of the following events: 

(a) An action or omission of Executive which constitutes a willful and intentional material breach of this Agreement or the Confidentiality
Agreement (defined below), including without limitation, Executive’s theft or other misappropriation of the Company’s proprietary information; 

(b) Executive’s commitment of fraud, embezzlement, misappropriation of funds or breach of trust in connection with Executive’s
employment; or 

  
 - 4 - 

 (c) Executive’s conviction of any crime which involves dishonesty or a breach of trust, or
gross negligence in connection with the performance of the Executive’s duties. 
 3.4. Definition of Disability. For purposes of
this Agreement “Disability” shall mean any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve
(12) months and renders Executive unable to perform the duties of General Counsel and Executive Vice President, Legal Affairs and Corporate Secretary. 

IV. STOCK ACCELERATION 
 4.1
Accelerated Vesting. In addition to any other right of acceleration that may be provided pursuant to any stock option plan or agreement pursuant to which Executive has been granted options to purchase shares of Common Stock of the Company, if
Executive’s employment is terminated due to an Involuntary Termination, the vesting of any unvested stock options and the lapsing of the Company’s repurchase right with respect to any shares of restricted stock held by Executive as of the
date of Executive’s Involuntary Termination shall accelerate such that the options shall become vested and the repurchase right shall lapse as to an additional twelve (12) months; provided that if such Involuntary Termination occurs
within twelve (12) months after a Change of Control (as defined below), then the vesting of all stock options and the lapse of the Company’s repurchase right with respect to all shares of restricted stock of the Company held by Executive
shall be accelerated completely so that one hundred percent (100%) of the shares of common stock covered by the stock options are fully vested and exercisable and the Company’s repurchase right has lapsed with respect to all shares of
restricted stock held by Executive. 
 4.2 Definition of Change of Control. For purposes of this Agreement, “Change of
Control” shall mean the occurrence of any of the following events: (i) an acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization,
merger or consolidation but excluding any merger effected exclusively for the purpose of changing the domicile of the Company), or (ii) a sale of all or substantially all of the assets of the Company (collectively, a “Merger”),
so long as in either case the Company’s stockholders of record immediately prior to such Merger will, immediately after such Merger, hold less than fifty percent (50%) of the voting power of the surviving or acquiring entity. 

V. RESTRICTIVE COVENANTS 
 5.1
Confidentiality Agreement. Executive shall sign, or has signed the Company’s form of Proprietary Information and Inventions Agreement (the “Confidentiality Agreement”) substantially in the form attached hereto as
Exhibit A. Executive hereby represents and warrants to the Company that she has complied with all obligations under the Confidentiality Agreement and agrees to continue to abide by the terms of the Confidentiality Agreement and further
agrees that the provisions of the Confidentiality Agreement shall survive any termination of this Agreement or of Executive’s employment relationship with the Company, including the noncompetition provisions of the Confidentiality Agreement.

  
 - 5 - 

 VI. OTHER PROVISIONS 

6.1 Limitation on Severance Benefits. In the event that any severance benefits provided for in this Agreement to Executive
(i) constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and (ii) but for this Section 6.1, would be subject to the excise tax
imposed by Section 4999 of the Code, then Executive’s severance benefits under Section 3.2 shall be payable either: 
 (a) in
full, or 
 (b) as to such lesser amount which would result in no portion of such benefits being subject to excise tax under
Section 4999 of the Code, 
 whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the
excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis, of the greatest amount of benefits under Section 3.2 notwithstanding that all or some portion of such benefits may be taxable under
Section 4999 of the Code. Any determination required under this Section 6.1 shall be made in writing by independent public accountants appointed by Executive and reasonably acceptable to the Company (the “Accountants”), whose
determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 6.1, the Accountants may make reasonable assumptions and approximations concerning
applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants
may reasonably request in order to make a determination under this Section 6.1. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 6.1. If a reduced amount
is to be paid under this Section 6.1, reductions in payments and/or benefits shall occur in the following order: (1) reduction of cash payments, (2) cancellation of accelerated vesting of stock awards other than stock options,
(3) cancellation of accelerated vesting of stock options and (4) reduction of other benefits (if any) paid to the Executive. 

6.2 Code Section 409A. This Agreement shall be interpreted to avoid any penalty sanctions under Section 409A of the Code and
the final regulations and any guidance promulgated thereunder (“Section 409A”). If any payment or benefit cannot be provided or made at the time specified herein without incurring sanctions under Section 409A, then such benefit
or payment shall be provided in full at the earliest time thereafter when such sanctions will not be imposed. All payments to be made upon a termination of employment under this Agreement may be made only upon a “separation of service”
under Section 409A. Notwithstanding anything to the contrary in this Agreement, if at the time of Executive’s termination of employment, Executive is a “specified employee” within the meaning of Section 409A, and the
deferral of the commencement of any severance payments or benefits otherwise payable pursuant to this Agreement as a result of such termination of employment is necessary in order to prevent any accelerated income recognition or additional tax under
Section 409A(a)(1), then the Company will not commence any payment of any such severance payments or benefits otherwise required hereunder (but without any reduction in such payments or benefits ultimately

  
 - 6 - 

 
paid or provided to Executive) that (a) will not and may not under any circumstances, regardless of when such termination occurs, be paid in full by March 15 of the year following
Executive’s termination (or two and one half (2  1⁄2) months after the close of the Company’s fiscal year, if later), and (b) are in excess of
the lesser of (i) two (2) times Executive’s then annual compensation or (ii) two (2) times the limit on compensation set forth in Section 401(a)(17) of the Code for the year in which Executive’s employment is
terminated and will not be paid by the end of the second calendar year following the year in which the termination occurs, until the first payroll date that occurs after the date that is six (6) months following Executive’s
“separation of service” with the Company (as defined under Code Section 409A). If any payments are delayed due to such requirements, such amounts will be paid in a lump sum to Executive on the earliest of (x) Executive’s
death following the date of Executive’s termination of employment with the Company or (y) the first payroll date that occurs after the date that is six (6) months following Executive’s “separation of service” with the
Company. For these purposes, each severance payment or benefit is designated as a separate payment or benefit and will not collectively be treated as a single payment or benefit. This provision is intended to comply with the requirements of Code
Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and
Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual
payment to Executive under Section 409A. Notwithstanding anything to the contrary set forth in this Agreement, to the extent that any amendment to this Agreement with respect to the payment of any severance payments or benefits would constitute
under Section 409A a delay or acceleration in a payment or a change in the form of payment, then such amendment must be done in a manner that complies with Section 409A(a)(4)(C). 

6.3 Indemnification. The Company hereby agrees to indemnify and hold the Executive harmless, to the fullest extent permitted by law and
as set forth in the Amended and Restated Certificate of Incorporation of the Company, from and against any expenses, including legal fees, and all judgments, fines and amounts paid in settlement and reasonably incurred in connection with legal,
administrative or investigative proceedings to which the Executive is made, or threatened to be made, a party by reason of the fact the Executive is or was a director or officer of the Company. 

6.4 Entire Agreement. This Agreement, the Confidentiality Agreement and any agreement pertaining to Executive’s stock options or
shares of restricted stock contain the entire agreement and understanding of the parties with respect to Executive’s employment by the Company and compensation payable to Executive by the Company and supersede all prior understandings,
agreements and discussions. This Agreement may only be amended or modified by a written instrument executed by Executive and the Chief Executive Officer of the Company pursuant to authorization by the Compensation Committee. 

  
 - 7 - 

 6.5 Notices. Any and all notices permitted or required to be given under this Agreement
must be in writing. Notices will be deemed given (i) on the first business day after having been sent by commercial overnight courier with written verification of receipt, or (ii) on the third business day after having been sent by
registered or certified mail from a location on the United States mainland, return receipt requested, postage prepaid, whichever occurs first, at the address set forth below or at any new address, notice of which will have been given in accordance
with this Section 6.4: 
  

			
	If to the Company:		Seattle Genetics, Inc.
			21823 30th Drive SE
			Bothell, WA 98021
			Attn: General Counsel
		
	If to Executive:		Jean Liu
			736 Candor Street
			Encinitas, CA 92024

 6.6 Non-Waiver. Failure to enforce at any time any of the provisions of this Agreement shall not be
interpreted to be a waiver of such provisions or to affect either the validity of this Agreement or the right of either party thereafter to enforce each and every provision of this Agreement. 

6.7 Separability. If one or more provisions of this Agreement is finally determined to be invalid or unenforceable, such provision will
not affect or impair the other provisions of this Agreement, all of which will continue to be in effect and will be enforceable, provided, however, that any such invalid provisions shall, to the extent possible, be reformed so as to implement
insofar as practicable the intentions of the parties. 
 6.8 Term. The employment of Executive under this Agreement shall be for an
unspecified term. The Company and Executive acknowledge and agree that Executive’s employment is and shall continue to be at-will, as defined under applicable law, and that Executive’s employment with the Company may be terminated by
either party at any time for any or no reason, and with or without notice. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages award or compensation other than as provided in
this Agreement. 
 6.9 Law. This Agreement shall be interpreted in accordance with the laws of the State of Washington. 

6.10 No Duty to Mitigate. Executive shall not be required to mitigate the amount of any payment contemplated by this Agreement (whether
by seeking new employment or in any other manner), nor, except as otherwise provided in this Agreement, shall any such payment be reduced by any earnings that Executive may receive from any other source. 

6.11 Legal Fees. In the event either party breaches this Agreement, the nonbreaching party shall be entitled to recover from the
breaching party any and all damages, costs and expenses, including without limitation, attorneys’ fees and court costs, incurred by the nonbreaching party as a result of the breach. 

  
 - 8 - 

 6.12 Counterparts. This Agreement may be executed in counterparts which when taken
together will constitute one instrument. Any copy of this Agreement with the original signatures of all parties appended will constitute an original. 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written. 

 

			
	COMPANY:
	
	SEATTLE GENETICS, INC.
		
	By:		/s/Clay Siegall
		
	Name:		Clay Siegall
		
	Title:		President and CEO

  

	
	EXECUTIVE
	
	/s/ Jean Liu
	Jean Liu

  
 - 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]